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ABSTRACT 
T cells play a vital role in the adaptive immune response against viral 
infections. Virus-specific T cells recognize infected cells through a 
heterodimeric surface receptor known as the αβ T cell receptor (TCR). The 
TCR recognizes a peptide epitope presented by a product of the major 
histocompatibility complex (MHC). All nucleated cells express class I MHC 
products, typically in association with one of thousands of “self” peptides. 
However, during a viral infection, “foreign” peptides derived from the expression 
of viral proteins would also be presented on the cell surface. T cells expressing 
TCRs that specifically recognize these viral peptide-MHC complexes (pMHC) 
can become activated and destroy the virus-infected cell. However, the immune 
system of many patients with chronic viruses has undergone a process of 
tolerance whereby the T cells are either non-existent or inactive. The ability to 
study the viral pMHC on infected cells would allow a greater understanding of 
anti-viral responses and the development of specific targeting molecules 
against these pMHC could lead to the generation of novel therapeutic 
interventions to control viral infections. The studies described here focus on 
these goals. 
Chapter 2 describes the characterization of two monoclonal antibodies 
that are specific for immuno-dominant hepatitis B virus epitopes, the core 
protein peptide 18-27 (Core18-27) and the envelope protein peptide 183-191 
(Env183-191), both restricted by the human HLA-A*02:01 class I MHC. Both 
murine monoclonal antibodies exhibited specificity and high affinity for their 
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respective epitopes. In addition, the antibodies were able to recognize pMHC 
generated exogenously by pulsing HLA-A*02:01+ T2 cells with the respective 
peptides, and also endogenous pMHC complexes produced by HBV infected 
cell lines. The antibodies were used further to quantify and visualize specific 
HBV pMHCs on the surface of various cell lines, allowing the study of how 
density and distribution of these pMHC ligands affected T cell activation. 
In Chapter 3, I sought to examine the use of soluble TCRs in comparison 
with a monoclonal antibody generated against the same antigen. To approach 
the question, the α and β chain genes of a TCR specific for the envelope 
protein peptide 183-191 (Env183-191) epitope were cloned from a T cell line and 
the extracellular domains were expressed in Escherichia coli. Characterization 
of the refolded, soluble TCR showed that only tetrameric forms bound 
specifically to Env183-191 pMHC in a surface plasmon resonance assay, or with 
peptide-pulsed target cells, consistent with the well-known low affinities of 
TCRs. To further explore the specificity of the TCR, I developed a sensitive 
bead-based avidity assay. Using this assay, a comparison between the TCR 
tetramer and the Env183-191 specific monoclonal antibody showed that although 
the tetrameric form of the soluble TCR had similar functional avidity for the 
Env183-191 pMHC as the monoclonal antibody, it required a higher density of 
pMHC ligands in order to achieve significant binding. Nevertheless, the assay 
revealed a difference in fine specificity of the TCR and the monoclonal 
antibody, consistent with evidence that the T cell clone could recognize a 
particular virus-variant (clade), which the antibody could not recognize.  
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Finally in Chapter 4, I used the sensitivity of the avidity-based assay 
described in Chapter 3 to develop a novel method for the in vitro engineering of 
T cell receptors expressed in a yeast display system. In view of the limitations 
imposed by the low affinity of soluble TCRs, protein engineering is necessary to 
improve the monomeric affinity (a process called affinity maturation). 
Conventional methods for screening yeast-displayed libraries of TCRs had 
used tetrameric pMHC or commercially available dimeric MHC-Immunoglobulin 
fusion molecules. To improve the sensitivity of the screening strategy, the 
bead-based assay was applied to a yeast display system with model TCRs of 
varying affinities. The pMHC-coated beads were able to significantly stain lower 
affinity TCRs that had previously not been isolated using the tetrameric and 
dimeric reagents. Furthermore, the assay was used in the screening of a 
single-chain TCR library, isolating not only high affinity mutants but also 
intermediate affinity mutants that would not have been selected by the other 
reagents. In the absence of high affinity solutions within libraries, these 
intermediate affinity mutants can be potential leads with which further 
engineering can be done, thus increasing the success rate of TCR engineering. 
They could also serve as TCRs with improved activities in adoptive T cell 
therapies, which are known to benefit from such intermediate affinity TCRs. 
The molecular probes available to specifically target peptide-major 
histocompatibility complexes are relatively uncommon and thus the capacity to 
study pMHC distribution and quantities has been limited. The key problems 
have been due to the fact that the natural receptors for the pMHC, the T cell 
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receptors, are difficult to express in soluble form and are of poor affinity. TCR-
like antibodies against a specific pMHC provide one possible solution, but they 
are difficult to generate, and their specificities are often not adequate (e.g. they 
bind MHC epitopes such that the peptide contribution to binding varies). In this 
thesis, I describe the characterization and applications of two such antibodies 
and a soluble TCR that are able to specifically target HBV pMHCs. I also 
describe the development of a new screening assay that would facilitate yeast 
display protein engineering in the generation of high affinity TCRs specific for 
pMHC. These probes provide opportunities to study the details of viral peptide 
presentation and anti-viral immune responses, and they also provide potential 
molecular therapies, with targeted delivery capacities that would aid the 
treatment and resolution of viral infections. 
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CHAPTER ONE 
 
INTRODUCTION 
 
The Immune System 
 The human body is constantly exposed to parasites, bacteria and viruses. 
However, infection is largely prevented with the help of the highly sophisticated immune 
system. The two branches of the immune system, innate and the adaptive are 
composed of a variety of cells and a myriad of proteins working together to recognize 
and eliminate these infectious pathogens. While the innate immune system represents 
the first line of defense against pathogens, the adaptive immune system involves a 
pathogen specific response to eradicate the infection and also provide long-term 
immunity through immunological memory. Although both systems differ in how they 
confer immunity against invading pathogens, immune responses elicited by either 
system have significant influence over the other and they work together to prevent 
pathogenic infections. 
 The innate immune system is the evolutionarily more ancient branch of the 
immune system; for example, both insects and mammals share similarities in pathogen 
recognition, signalling pathways, and effector mechanisms (93). Innate responses to 
infection are the first to develop, are generally not antigen specific, and react broadly to 
various pathogens. Components of the innate immune system range from physical 
barriers to pathogens, such as skin epithelium and mucus layers in the respiratory and 
gastrointestinal tracts, to soluble mediators such as defensins and complement 
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proteins, to immune cells such as macrophages, neutrophils, eosinophils and natural 
killer (NK) cells that elicit a variety of distinct immune responses (60, 74, 101).  
The major requirement in an immune response is the ability of immune cells to 
differentiate between host (self) and foreign (non-self) components. Innate immune cells 
recognize pathogens through the expression of “pattern recognition receptors” (PRRs) 
such as mannan-binding lectin (MBL), C-reactive protein (CRP) and the Toll-like 
receptors (TLRs) (72, 125, 194). MBL and CRP are associated with the activation of the 
complement pathway in the innate system. MBL binds to terminal mannose residues 
found on the surface of many microorganisms, and associates with the MBL-associated 
serine proteases (MASP) MASP1 and MASP2. The serine proteases are activated and 
subsequently they initiate the lectin pathway of complement by cleaving C2 and C4 
proteins (60). CRP on the other hand functions as an opsonin, binding to 
phosphorylcholine on the surface of bacteria, and then with complement C1q, triggering 
the classical complement pathway (4).  
 TLRs are a family of receptors with broad specificity, recognizing pathogen 
associated molecular patterns (PAMPs) that are molecular motifs uniquely associated 
with pathogens. PAMPs include molecules such as the flagella of bacteria, 
lipopolysaccharide (LPS) on gram-negative bacteria, teichoic acids on gram-positive 
bacteria, the un-methylated dinucleotide CpG motif in bacteria DNA, double and single 
stranded viral RNAs, glycolipids and zymosans of yeast and fungi (194). Immune cells 
such as macrophages, dendritic cells, and mast cells utilize TLRs to recognize invading 
pathogens and upon binding, the receptors initiate an inflammatory response that 
involves the secretion of cytokines such as IL-1, IL6, IL-8, TNF-alpha, type I interferons, 
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and chemokines that help recruit other immune cells to the site of infection (82, 140, 
191). Phagocytic cells such as macrophages and neutrophils also express other 
receptors such as the complement receptors, scavenging receptors and the Fc 
receptors (specific for the Fc, “Fragment crystalizable”, region of antibodies) that are 
able to bind to opsonized pathogens and activate phagocytosis. These cells engulf and 
internalize pathogens in intracellular phagosomes and subsequently degrade them with 
an arsenal of molecules such as defensins, lyzosyme, hydrolases and toxic reactive 
oxygen species including superoxide free radicals, hypochorite, hydrogen peroxide and 
nitric oxide (27, 84). The adaptive immune system is the more recently evolved branch 
of the immune system, found only in vertebrates (52). Whereas innate immune 
responses are not considered specific for each pathogen, adaptive immune responses 
are highly specific and require considerably more time to develop, especially when a 
pathogen is encountered for the first time. More importantly, adaptive responses also 
provide long lasting immune protection after initial contact with pathogens. Adaptive 
immunity involves two general classes of responses; humoral and cellular immune 
responses, with B and T lymphocytes being the main effector cell types, respectively 
(152). As indicated, the essential feature of the immune system is the ability to 
distinguish between self and non-self. B cells and T cells express B cell receptors 
(BCRs) and T cell receptors (TCRs), members of the immunoglobulin superfamily, in 
order to identify foreign pathogens (Figure 1.1) (222). Each B cell and T cell expresses 
a potentially unique BCR or TCR that is specific for a particular antigen, giving rise to a 
diverse population of lymphocytes, each having their own specificity. This vast diversity 
in antigen specific receptors is a product of a unique somatic recombination process 
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mediated by two recombination activating gene (RAG) enzymes, RAG-1 and RAG-2 
(144, 173). It has been hypothesized that during evolution, insertion of transposable 
elements into primordial immunoglobulin genes generated the gene segments that 
encode the BCR and TCR (3, 197). Further duplications of the individual gene 
segments, known as variable (V), diversity (D), joining (J) and constant (C) gene 
segments, could then have given rise to the genetic diversity of the antigen receptors of 
the present day B cell receptor and T cell receptor. 
 
B cells and antibodies 
 B cells and T cells originate from the same hematopoietic stem cells. While T 
cells develop in the thymus (hence the name), B cells develop in the bone marrow. B 
cells produce antibodies, molecules that bind to antigens such as pathogens and toxins, 
thus neutralizing them by mediating antibody-dependent cell-mediated cytotoxicity 
(ADCC), phagocytosis, and/or activation of complement-mediated immunes responses 
(156). An antibody has often been illustrated as a “Y” shaped molecule, made up of two 
heavy chains and two light chains, respectively encoded by the IgH gene containing V, 
D, J, and C segments and the IgL gene containing V, J, and C segments.  Each arm 
(Fab, for “Fragment antigen binding”) of the antibody contains one variable and one 
constant domain from each chain forming the antigen binding region, while the tail 
region (Fc) is made up of constant domains of the heavy chain, which can interact with 
Fc receptors or complement.  
 B cells undergo several stages in development during which the genetic 
recombination of the V, D and J segments at the IgH locus occurs, followed by the V 
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and J recombination of IgL locus. Three complementarity determining regions (CDRs) 
are formed by loops of approximately 5 to 10 amino acid residues that are present in 
each variable domain. These six CDR loops (3 in the VH and 3 in the VL) provide the 
antigen-binding diversity of antibodies, determining the specificity and affinity for their 
respective antigens. CDRs 1 and 2 are encoded by the V gene segment of heavy and 
light chains, while the CDR3 is encoded by the junction of the recombined VDJ (heavy 
chain) and VJ (light chain) genes and is thus the most variable. Each light chain 
consists of a single variable domain and a single constant domain while each heavy 
chain consists of a single variable domain and either three or four constant domains, 
depending on the class of antibody. There are five classes of antibodies in mammals: 
IgA, IgD, IgE, IgG and IgM, each encoded by their respective heavy chain constant 
region genes, α, δ, ε, γ, and µ (119, 187). During the initial stages of the development of 
B cells in the marrow, two heavy chains consisting of the recombined VDJ and the µ 
constant domain associates with two VJ recombined light chains on the cell surface to 
form a membrane bound IgM. This complex along with a cytosolic heterodimeric 
signaling complex made up of CD79a (Ig-α) and CD79b (Ig-β) forms the BCR complex 
in immature B cells (133). At the end of the maturation process in the bone marrow, B 
cells expressing both membrane bound IgM and IgD migrate from the marrow as naïve 
B cells to the peripheral lymphoid organs (e.g. lymph nodes) where they mature further 
(36). Upon binding and activation of the B cell by its specific antigen, it proliferates 
rapidly, begins to make soluble antibodies and differentiates into an antibody-secreting 
plasma cell. During the replication process, IgH and IgL loci also undergo a process 
known as somatic hypermutation in which a high rate of point mutations generates 
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further diversity in the variable domains of the antibody chains (119). The B cells then 
undergo clonal selection and expansion based on antigen binding of those antibody 
mutants that have enhanced affinity for the antigens (i.e. affinity maturation).  
 Another process that occurs after B cell activation is isotype class switching, a 
further recombination process in the heavy chain loci occuring at the constant gene 
segments. As indicated, there are various classes of antibodies produced by B cells. 
While naïve B cells only produce membrane bound IgM and IgD, activated B cells 
secrete IgM, IgA, IgE or IgG antibodies. During the maturation of the B cell, DNA 
encoding the VDJ recombined variable domain of the heavy chains can undergo a 
downstream class switch recombination involving the constant γ, α or ε segments, 
resulting in a gene that now encodes for a different isotype, i.e. IgG, IgA or IgE 
respectively. This process preserves the antigen specificity of the antibodies but varies 
the effector function of the antibodies due to differences in Fc regions; the process is 
influenced by cytokines produced by neighbouring T cells in the lymphoid organs (157). 
 
T cells and T cell receptors 
 T lymphocytes are the main effectors of cellular immune responses of the 
adaptive immune system (152). There are two major classes of T cells that are 
distinguished by the co-receptor expressed on the cell surface. Helper T cells express 
CD4 and cytotoxic T cells (also known as CTLs, cytotoxic T lymphocytes) express CD8. 
Helper T cells consist of a diverse group of CD4+ T cells that play distinct roles by 
secreting a diverse collection of cytokines, depending on the lineage. The classical 
Th1/Th2 dichotomy established in the late 80s (137) has now grown to include Th17 cells, 
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natural regulatory T cells (nTreg, developed in the thymus), induced regulatory T cells 
(iTreg), T follicular helper cells (Tfh), Th22 and Th9 cells (213, 229). The differentiation of 
naïve CD4+ T cells is highly dependent on the cytokine milieu present during CD4+ T cell 
activation. Activation results in the upregulation of distinct transcription factors and 
subsequent gene expression profile associated with the various lineages. For example, 
Interleukin-12 (IL-12) and Interferon-gamma (IFN-γ) are important for Th1 differentiation, 
IL-2 and IL-4 are important for Th2 cells, and, transforming growth factor β (TGF-β) and 
IL-6 are important for Th17 cells. The subsequent upregulation of the transcription 
factors T-bet, GATA-3 and RORγt results in the differentiation of the naïve CD4+ T cell 
into the Th1, Th2 and Th17 lineages, respectively (213).  
There are also a unique group of CD4+ T cells known as the regulatory T cells 
(Treg). These T cells operate to suppress immune responses of other cells, providing a 
self-checking system to prevent excessive responses that can lead to various diseases 
such as autoimmune diseases such as rheumatoid arthritis, systemic lupus 
erythematosus, and also immune mediated pathogenesis due to elevated levels of 
inflammation. 
The helper CD4+ T cell lineages perform diverse functions in the overall immune 
response. Th2 cells secret IL-4 and IL-5, cytokines that stimulate B cell proliferation and 
promote the class switching process in antibody production, and IL-13 that induced IgE 
class switching and also acts on epithelial and smooth muscle cells in the lung or 
intestinal compartments to increase mucus production, goblet cell metaplasia and 
airway hyper-responsiveness (AHR) (146). Thus Th2 mediated immune responses are 
commonly associated with immunity against helminths and allergens resulting in 
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inflammatory diseases such as asthma or type I hypersensitivity. Th1 cells on the other 
hand are associated with immune responses leading to delayed-type or type IV 
hypersensitivity (DTH) and protection against intracellular pathogens such as viruses (1). 
The primary cytokine secreted by Th1 cells, IFN-γ, is the only type II interferon, and is a 
potent factor for the activation of macrophages, induction of IgG2a antibody class 
switching in B cells and regulation of numerous genes that are involved in antigen 
presentation pathways and antiviral immunity (26, 177).  
 The CD8+ cytotoxic T cells (CTL), in addition to Th1 cells, are involved in immune 
responses against intracellular pathogens (91, 223). CD8+ T cells produce antiviral 
cytokines such as IFN-γ but they also offer protection directly killing the host cells (called 
target cells) that are required for pathogen replication. Target cell lysis is accomplished 
by inducing apoptosis in the target cell via two different mechanisms (182). One 
involves a membrane bound protein known as the Fas ligand, which binds and clusters 
the death receptor Fas expressed on the surface of the target cells. The adaptor Fas-
associated protein with Death Domain (FADD) is then recruited to the cytosolic death 
domain of the Fas receptors; these in turn recruit the zymogen form of caspase-8 
through its death effector domain (DED), forming the death-inducing signalling complex 
(DISC). Clustering of the pro-caspase-8 proteins results in their activation by 
autoproteolysis and the active caspase-8 goes on to cleave and activate effector 
caspases such as caspase-3, leading to apoptosis (111). Another mechanism by which 
cytotoxic T cells induce the death of their target cells involves the release of intracellular 
granules that contain cytotoxic machinery. These secretory granules contain perforin, a 
protein that polymerizes in target cell membranes to form transmembrane channels 
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analogous to those formed by complement proteins. The granules also contain serine 
proteases such as granzyme B that enter the target cells through the perforin channels, 
cleave and activate pro-caspases in the target cell, and thus initiate apoptosis (121).  
 Regardless of the function of the T cell, specificity is determined by the 
membrane-bound T cell receptor. Similar to the BCR on B cells, each T cell expresses a 
single variant of the TCR. However T cells are activated by a particular group of cells 
known as the antigen presenting cells (APCs) in the peripheral lymphoid organs. Most 
importantly, they also only recognize antigens in the form of short peptide fragments 
that are presented by surface molecules encoded by the major histocompatibility 
complex (MHC) (55). Just as there are two major classes of T cells (CD8+ and CD4+T 
cells), there are also two major classes of MHC products, class I and class II. The co-
receptors CD4 and CD8 not only define the T cell classes, but they function by binding 
to class II and class I MHC products, respectively. This binding facilitates both the 
specificity and sensitivity of the T cells, in part by binding the corresponding peptide-
MHC complex (pMHC) cooperatively with the TCRs (110), in the formation of what has 
been termed the “immunological synapse”.  
The TCR is a heterodimeric receptor consisting of an α chain and a β chain, each 
made up of a single variable and a single constant immunologobulin-like domain (Note: 
there is also a γδ heterodimer that is found on a smaller fraction of T cells) (15, 77, 129). 
Similar to the light chain and heavy chains of the antibody, the alpha and beta chains of 
the TCR are encoded by multiple gene segments: V, J, C segments for the alpha chain, 
and V, D, J and C segments for the beta chain (114). Diversity of the TCR is generated 
by the same RAG mediated recombination process as antibodies, during development 
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of the T cell in the thymus (174). During thymic development, T cells undergo rigorous 
selection to ensure that the TCR on a mature T cell is both MHC-restricted yet not 
overtly self-reactive. After recombination of the TCR genes, immature thymic T cells 
express both CD4 and CD8 (double positive), along with their unique TCRs. They 
undergo two selection processes. The double positive T cells first undergo “positive 
selection” in which only those cells that express a TCR that binds to self-peptide MHC 
complexes expressed by cortical epithelial cells in the thymus receive a survival signal. 
T cells that bind to either class I or class II pMHCs develop into CD8+CD4- or CD4+CD8- 
T cells, respectively (193). Cells that fail to express a functional, MHC-binding TCR 
undergo apoptosis.  
The surviving T cells are further screened for self-reactivity in the medulla where 
APCs such as dendritic cells and thymic epithelial cells will present a repertoire of self-
peptides to the maturing T cells, with the help of the transcription factor autoimmune 
regulator (AIRE) (145). At this stage, T cells that bind too strongly to these cells via a 
TCR-pMHC interaction will die by apoptosis and undergo deletion in a process known 
as “negative selection” or tolerance induction. Thus, mature T cells that migrate from the 
thymus have undergone selection for those TCRs that have a low affinity for self-
peptide MHC, and against those TCRs that have too high of an affinity for self-peptide 
MHC.  
 
Antigen Processing and Presentation 
 Proteins encoded by the major histocompatibility complex (MHC) are cell surface 
molecules that bind short peptide fragments and “present” them to T cells. The peptide-
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MHC complex is recognized by a T cell receptor. As indicated, there are two major 
classes of MHC molecules, class I recognized by CD8 and class II recognized by CD4 
(142). MHC class I molecules are dimers composed of a membrane bound α chain (also 
known as the heavy chain) and a smaller non-covalently associated β2-microglobulin 
molecule. MHC class II molecules are dimers composed of two similarly sized 
membrane bound α and β chains. Both class I and class II molecules form similar three-
dimensional structures with four domains each. The peptide binding cleft is formed by 
two parallel alpha helices lying above a beta sheet; the two helices are formed by 
domains α1 and α2 of the MHC class I molecule and by domains α1 and β1 of the MHC 
class II molecule (122). The primary difference between the peptide-binding clefts of the 
class I and class II molecules is that the ends are more open in class II, allowing the 
peptide N- and C-termini to extend through and thus accommodating longer peptides. In 
contrast, in MHC class I molecules the N- and C-termini of the peptides are generally 
buried within the molecule, such that shorter peptides are present. Hence, there is a 
subsequent difference in the length of peptides bound in MHC class I and class II 
molecules. The peptides found in complex with class I MHCs are short, usually 8-10 
peptides in length, whereas those bound in class II are longer with at least 13 amino 
acids. Also, as the ends of the peptides in the pMHC class I complex are buried in the 
molecule, conserved residues known as anchor residues make the main stabilizing 
interactions while the binding cleft in the MHC class II is more permissive (45, 65).  
In humans, each individual inherits three MHC class I genes (HLA-A, -B and -C) 
coding for the heavy chain, and three MHC class II genes (HLA-DP, DR, DQ) coding for 
the α and β chains from each parent. β2-microglobulin is conserved and coded by a 
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gene that is not related to the MHC family of genes. Among the population, most of the 
MHC genes further exist in one of hundreds of possible alleles, making MHC genes 
both polygenic and highly polymorphic (97, 158). Polymorphisms in each allele include 
residues in the peptide binding pocket, hence each MHC protein would be able to 
present a different spectrum of peptides. These features allow a greater range of 
potential pathogenic antigens to be recognized by T cells. However, polymorphisms are 
also associated with either enhanced or reduced responsiveness to some pathogenic 
organisms, as these polymorphisms can affect binding to either self-peptides (and thus 
affect the processes of thymic selection) or they can influence the binding of the 
pathogenic peptides. For example, recent studies of HIV have shown that there is an 
association between elite responders and MHC class I polymorphisms (39). 
 The peptides presented by the MHC class II and I molecules differ in their 
intracellular processing pathways (81). MHC class II molecules present peptides that 
originate from endosomes and are expressed mainly by professional antigen-presenting 
cells. APCs such as macrophages and dendritic cells take up extracellular pathogens 
and antigens via phagocytosis or endocytosis. The pathogens are broken down and the 
proteins are then degraded into smaller fragments by acid proteases such as 
cathepsins that are present in the late endosome and lysosomes. Proteins that bind to 
the BCR on B cells are also internalized by receptor-mediated endocytosis and 
processed similarly. Newly synthesized MHC class II αβ dimers in the endoplasmic 
reticulum (ER) are associated with an invariant chain to stabilize the molecule and to 
prevent the class II molecule from binding any peptides found in the ER. The invariant 
chain also targets the delivery of the class II molecule to the endosomal compartment 
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where acid proteases will cleave the invariant chain, leaving a short fragment called 
CLIP (class II-associated invariant chain peptide) still bound in the binding site of the 
class II molecule. Pathogenic peptides are still unable to bind to the class II molecule 
due to the presence of CLIP until a MHC class II-like molecule known as HLA-DM 
promotes the dissociation of CLIP and stabilizes the empty class II molecule until an 
antigenic peptide is loaded into the binding cleft. Another function of the HLA-DM is also 
to remove weakly binding antigens in a process known as peptide editing (7), ensuring 
only the presentation of stable antigen peptide MHC complexes. Finally, the stable 
complex is transported to the surface of the cell, where it can stimulate CD4+ T cells.  
The MHC class I molecule is expressed by all nucleated cells. These molecules 
express either self peptides or antigen fragments, e.g. derived from viral proteins that 
are synthesized in infected cells. Cytosolic proteins, including the viral and self-proteins, 
and misfolded proteins in the ER are continuously degraded by the proteasome (92). 
The peptide fragments formed are then delivered into the ER as potential ligands for the 
MHC class I molecule by ATP-binding cassette (ABC) proteins in ER membrane known 
as ‘transporters associated with antigen processing-1 and -2’ (TAP-1 and TAP-2). The 
newly synthesized class I heavy chain is refolded with the help of the chaperon protein 
calnexin, followed by calreticulin. The refolded heavy chain then associates with β2-
microglobulin and along with tapasin and Erp57, forms the peptide-loading complex in 
the lumen of the ER. The TAP complex formed by TAP-1 and TAP-2 then associate 
with this peptide-loading complex and transport peptides from the cytosol to the 
proximity of the empty MHC class I molecule. In an uninfected cell, self peptides are 
loaded onto the MHC class I molecule and the peptide-loading complex dissociates, 
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allowing the refolded MHC molecule to be transported out of the ER to the cell surface. 
However, if the cell is infected by a virus, peptides derived from viral proteins that are 
being produced in high quantity for the replication of the virus can be loaded into the 
binding cleft of the MHC class I molecule and presented on the cell surface for 
recognition by a CD8+ T cell, leading to destruction of the infected cell.  
 
The Hepatitis B Virus 
 Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic member of the 
hepadnaviridae family that infects only humans and chimpanzees. Other related viruses 
infecting ground squirrels, woodchucks and waterfowl such as geese and ducks have 
also been found. HBV infection in most adults is acute, and ultimately viral clearance is 
achieved. However, an estimated 350 million people in the world are chronically 
infected with HBV, leading to almost a million deaths a year from HBV related 
complications. A highly effective vaccine (Recombinvax HB®) consisting of recombinant 
surface antigen (HBsAg) produced in yeast cells has been developed (205) and has 
been successful in preventing new infections in countries that introduced vaccination 
programs. Unfortunately, the prophylactic vaccine produced only transient anti-viral 
effects in chronic patients, with limited effective control of the infection.  HBV causes an 
inflammatory state in the liver and failure to clear the virus leads to chronicity, liver 
cirrhosis, and eventually hepatocellular carcinoma (HCC). Although the hepatitis B virus 
does not directly cause the cellular death associated with liver diseases, pathogenesis 
is attributed to the corresponding immune response (46, 68, 86). In acute patients, a 
robust immune response successfully eradicates the viral infection with minimal injury or 
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lasting effects on the liver. However in chronic patients, a poor immune response allows 
the virus to persist and sustained liver disease with associated liver cell destruction and 
regeneration, and inflammation. Thus the chronic liver cell injury presents a potential 
oncogenic state; after a long period of time there is increased probability of the 
accumulation of genetic aberrations, random viral integration into the genome, and 
other viral factors that affect cellular pathways, eventually contributing to the 
development of HCC.  
 
HBV biology and antigens 
 The hepatitis B virus is an enveloped virus with a partially double-stranded, 
relaxed circular DNA (rcDNA) genome of 3.2kb that consist of a complete minus strand 
and a partially synthesized plus strand (Figure 1.2) (179, 198). Viral reverse 
transcriptase is attached at the 5’ end of the minus strand and a short RNA is attached 
to the 5’ end of the plus strand. During infection, the reverse transcriptase and RNA 
fragment are removed and the rcDNA is converted into a covalently closed circular DNA 
(cccDNA). This cccDNA then serves as the template for the transcription of four mRNAs 
that encode for the core and envelope structural proteins and the non-structural proteins 
pre-core, polymerase and X proteins. The largest 3.5kb mRNA is greater than the HBV 
genome itself and serves as the pre-genomic RNA that is packaged into viral capsids 
and used as a template for the replication of the HBV DNA genome. The pregenomic 
mRNA also contains three open reading frames that code for the core, pre-core and 
polymerase proteins. The core proteins, also known as the hepatitis B core antigen 
(HBcAg), are main structural proteins that form the viral capsids. The pre-core protein, a 
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longer version of the core protein, with an extended N-terminal sequence coding for a 
signal peptide, does not play a part in the viral particle formation but is instead 
translocated to the ER where further processing results in secretion of the protein as an 
extracellular form of the HBcAg known as the HBeAg. The polymerase protein is 
translated from an internal ribosomal initiation site in the pregenomic mRNA. The 
multifunctional polymerase protein is not only a reverse transcriptase, but also a DNA 
polymerase, and an RNAase, and it contains an amino-terminal domain that functions 
as a protein-primer during reverse transcription of the viral pregenome.  
 The envelope consists of three structural proteins encoded in the envelope open 
reading frame (ORF). These three overlapping proteins called small (S), medium (M) 
and large (L) are translated from three different start codons in the ORF and contain the 
hepatitis B surface antigen. In addition to the S protein, the additional domain in the M 
protein is called the pre-S2 domain, while the L protein contains this and an extra pre-
S1 domain. All three proteins are essential components of the HBV virion (also known 
as the Dane’s particle) and are transmembrane proteins that form multimers via 
disulphide bridges between cysteines in the S domains (202). Interestingly, smaller non-
infectious particles containing predominantly the S and M proteins are made in excess 
of Dane particles, accumulating in the blood of infected patients. On the other hand, the 
excess L proteins form long filamentous particles that are not secreted but are 
accumulated in the ER causing the ER to be enlarged, giving the infected hepatocyte 
the histologically characteristic “ground glass” appearance (210). The pre-S1 domain of 
the L protein functions as a ligand for the binding of the core proteins in the capsids 
prior to the assembly of the viral particle that eventually buds off from the ER membrane. 
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The pre-S1 domain of the L proteins is found in the cytosolic side of the viral membrane 
to interact with the core proteins during viral particle assembly (147). A conformational 
change in the protein causes pre-S1 domain to be displayed outside the viral particle. 
While the route of infection of the HBV virus is still unknown, there is evidence that the 
translocated pre-S1 domain of the L protein is an important substrate for the viral 
receptor as neutralizing antibodies against epitopes in the pre-S1 domain are able to 
attenuate viral replication (179). Although numerous studies have suggested that cell 
membrane proteins such as annexin V, apolipoprotein H and the transferrin receptor 
liver all interact with HBV envelope proteins, it has not been demonstrated that they are 
involved in the infection of hepatocytes (86). 
 The fourth open reading frame in the HBV genome codes for a transcriptional 
transactivating protein known as the X protein (HBx) (179, 224). In vitro studies have 
shown that the X protein is able to activate the transcription of numerous host genes 
and also viral genes, stimulate signal transduction pathways and bind various host 
proteins. However, the overall physiological function of X is still not very clear although it 
has been shown to be essential for infection in vivo but not in vitro.  
 
Immune responses to HBV infection 
 Virus infections usually induce an innate immune response involving the 
production of type I interferons (IFN-α and -β), leading to the upregulation of genes that 
promote an environment inhibiting the replication of virus (171). However, hepatitis B 
virus infections in animal models have showed that the HBV virus can elude innate 
immune detection systems such as the Toll-like receptors, preventing induction of IFN-
α/β (218). The kinetics of HBV replication in the body provides a possible explanation. It 
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has been observed that HBV replication has an initial lag phase of 4-7 weeks, during 
which viral DNA and antigens are not detectable in serum or the liver; after this, the 
virus undergoes logarithmic replication in which most hepatocytes are infected (219). 
Since innate immune responses were not detected during the lag period, the absence of 
HBV replication does not appear to be a consequence of active immune suppression by 
the virus. Another possible strategy adopted by the virus to evade the innate immune 
system is to retain its transcriptional template in the nucleus, away from the innate 
sensing molecules. In addition, the viral mRNA resembles host cellular transcripts, with 
a 5’ cap and 3’ polyadenylation and also by encapsulating its replicating genome in 
protein capsid particles in the cytoplasm (179, 219).  
 The adaptive immune system plays the major role in controlling HBV infections 
(20, 21, 160). A robust immune response mounted by the adaptive immune system is 
associated with the clearance of HBV in acute infections whereas a weak and transient 
response is highly correlated with chronic infections (69, 104, 215). In particular, robust 
T cell responses, both CD8+ and CD4+ T cells are found in patients that resolve 
infection. Th1 cytokines such as IFN-γ and TNF-α contribute to viral control but 
importantly, CD4+ T helper cells appear to play an important role in inducing CD8+ T cell 
responses against HBV infection; e.g. vigorous CD4+ responses coincide with CD8+ 
responses. Viral epitopes that trigger these immune responses have been well studied 
for both CD4+ (67) and CD8+ T cells (19, 141, 159, 185). More importantly, studies with 
MHC HLA-A2+ patients have also allowed the identification of immunodominant 
epitopes; Core 18-27 (124) and Env 183-191(215) that make up the majority of CD8+ 
immune responses. 
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 In addition, while CD8+ T cells aid in the control of HBV by eliminating infected 
hepatocytes, B cells provide humoral immunity against HBV infection mainly by 
secreting antiviral antibodies to neutralize viral particles. Detection of antibodies against 
the various hepatitis antigens in the sera of patients is commonly used as one 
diagnostic marker for the stages in infection (160). Anti-HBcAg IgM is the first antibody 
to develop during an acute infection and HBcAg IgG is commonly found in circulation 
post infection; anti-HBeAg antibodies and anti-HBsAg antibodies develop later, and help 
in both resolution of the infection and providing protective immunity. The recombinant 
HBsAg vaccine stimulates the immune system to produce the neutralizing anti-HBsAg 
antibodies and have since been successful in reducing HBV incidence in the last 30 
years (103).  
 
Chronic HBV infections and hepatocellular carcinoma 
 Chronic infections in patients occur when immune responses of the adaptive 
immune system fail. While cytotoxic CD8+ T cells in the control of HBV infection are 
without doubt important, the pathogenesis of liver disease during chronic infections can 
also be attributed to weak CTL responses (123). Factors contributing to the lack of a 
robust immune response are unclear but studies have shown that T-cell anergy could 
be due to high viral load. The viral precore (HBeAg) does not play a part in virus 
replication but may play a part in inhibiting the immune system. In transgenic mouse 
models, the HBeAg has been shown to anergize antigen specific T cells and suppress 
antibody production (40). In chronic patients with high levels of HBsAg in their sera, 
antigen specific T cell responses were weak and had altered pMHC binding (161). 
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Mutations in immunodominant viral antigens have also been found in chronic patients, 
allowing the mutant virus to evade immune surveillance or antagonize T cell activation 
(18, 22). Lastly, down regulation of MHC class I molecules had been observed in animal 
models (135) while the HBx protein has been shown to be able to inhibit processing by 
reducing the proteasome activity when overexpressed (98).  A reduction in MHC 
expression and processing capacity would further allow the virus to elude immune 
detection. 
 Although the hepatitis B virus is non-cytopathic, cytotoxic T cells that recognize 
infected hepatocytes rapidly induce them to undergo apoptosis. Secretion of 
chemokines such as CXCL9 and CXCL10 induced by IFN-γ results in the recruitment of 
inflammatory cells, including virus-nonspecific cells, to the liver (106). These non-
specific immune cells contribute to the necroinflammatory state of the infected liver by 
further secretion of inflammatory cytokines and hepatocytes death. Liver cells are 
terminally differentiated cells with a unique regenerative capacity in which healthy 
hepatocytes rapidly divide to replace destroyed cells in response to liver injury. Thus, in 
an acute infection, infected hepatocytes are successfully eliminated and hepatocellular 
regeneration ensures that the organ is fully recovered and the reparative processes are 
turned off when viral clearance that been achieved. However, when the immune 
response is inefficient in eradicating the virus in chronic patients, persistent 
inflammation in the liver results in continuous low-level destruction of hepatocytes that 
accumulates into fibrosis, cirrhosis and eventually leads to the development of 
hepatocellular carcinoma (86).  
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Engineering TCRs and Antibodies Against HBV pMHCs  
 Products of the major histocompatibility complex present peptides to T cells to 
facilitate antigen specific immune responses. The peptides presented by MHC class I 
proteins derived from cytosolic proteins may originate from viral proteins but also self-
proteins leading to the discovery of tumor associated antigens (28, 168) that are 
presented by MHC proteins on the surface of tumor cells. The use of soluble multimeric 
pMHC complexes, described first in 1996 by Altman et al (6), contributed significantly to 
the study of specific T cell populations. Conversely, there are few tools to study specific 
pMHC complexes on the surface virally infected or tumor cells. Soluble forms of the T 
cell receptor would be the most obvious solution but the low affinity and stability of 
TCRs as recombinant soluble molecules has made it difficult to use them as detection 
tools (9, 169), 
Monoclonal antibodies with TCR-like specificities also offer a possible alternative 
(139, 149). The ability to have tools that target specific pMHC complexes would enable 
the study of the expression and distribution of these complexes on the surface of tumor 
cells and virally-infected cells. Visualization and quantification of specific pMHC 
complexes during diagnosis of patients would also aid in deciding the appropriate 
therapeutic measures of the best efficiency, especially in the administration of TCR 
gene transfer therapy (178). Furthermore, with the ability to target specific pMHC 
presented on tumor or virus-infected cells, directed delivery of drugs, immunotoxins, 
cytokines or therapeutic molecules, such as bi-specific antibody fusions could be 
enabled (13, 35, 63, 136, 216).  
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Soluble T cell receptors 
 The first structures of both a human and a mouse αβ TCR was published in 1996 
(75, 77). Unlike antibodies, TCRs are membrane bound receptors with a hydrophobic 
transmembrane domain; thus, only the extracellular domains of the individual TCR 
chains were expressed and crystalized. Several groups had introduced additional 
stabilization domains such as jun/fos leucine zippers to aid in the refolding of the 
heterodimer (89, 221). Further engineering to increase the stability of the recombinant 
TCR have included the introduction of non-native disulfide bonds to replace the native 
bond formed by cysteine residues found in the stalk domain of the α and β chains that is 
excluded in the truncated construct. One strategy adopted was the use of C terminal 
extensions to the constant domains of the individual chains (188) while another group 
introduced the cysteine residues through rational design in the constant domains of the 
α and β chains (30). Mutagenesis at position 48 of the α-constant domain and 57 of the 
β-constant domain was done to introduce two cysteine residues that would be 
positioned in close proximity based on available structure of the constant domains, 
allowing a disulfide bond to be formed. Various eukaryotic expression systems such as 
insect cells and Chinese hamster ovary cells have been used with some success (8, 77, 
89, 211). However, some soluble TCRs were in an Escherichia coli expression system 
and refolded from inclusion bodies, with the benefits of higher yields with lower costs 
(30, 56, 75, 188, 207, 220).  
 T cell receptors have low affinities, with Kd values in the range of 1-100µM for 
their respective pMHC ligands, and with binding half-lives of only a few seconds (55). 
While B cell-derived antibody genes undergo somatic hypermutation after B cell 
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activation leading to the generation of mutants with enhanced affinity for the antigen. 
TCR genes do not undergo somatic hypermutation (71). Furthermore, during 
development in the thymus, only TCRs with very low affinity for self peptide-MHC are 
selected after rounds of positive and negative selections. One strategy used in an 
attempt to overcome the low affinity involved TCR multimers (115, 190), analogous to 
soluble pMHC tetramers (6). Laugel et al showed that the increased avidity was able to 
allow the HTLV-1 transcription factor Tax peptide specific A6 TCR and the influenza A 
matrix antigen specific JM22 TCR to exhibit 1339- and 444-fold slower dissociation rate 
than their monomeric interactions respectively. The increased avidity in these tetrameric 
molecules, and higher order oligomers using quantum dot scaffolds, allowed them to be 
used to stain cells (9, 115, 190). However, an important caveat to the use of such 
multimeric molecule is that the avidity benefits may be negligible with low physiological 
surface antigen densities (9). Another solution to the low natural affinity of TCR for their 
pMHC ligands is the enhancement of monomeric affinity by in vitro protein engineering, 
using the process of directed evolution. Mutant libraries are generated and screened for 
higher affinity variants using various techniques such as phage display (118), yeast 
surface display (47, 95, 108) and mammalian cell display (41). This strategy generated 
TCRs with improved affinities in the range of picomolar to nanomolar, allowing cell 
staining with monomeric TCR molecules. 
 
TCR-Like antibodies 
 Antibodies with TCR-like specificities have been generated by several groups as 
tools to study antigen presentation, for directed delivery of payloads, or as specific 
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inhibitors of T cell activation (113, 138, 148, 151, 162). Although there has been some 
success with conventional methods, i.e. hybridoma or immunization techniques, to 
generate antibodies with TCR-like specificities, such antibodies are still rare as B cells, 
unlike T cells, do not require MHC-restriction in their specificities (i.e. most of the 
antibodies are not directed at the peptide, but bind to the MHC alone).  However, the 
use of large phage-display libraries has allowed the isolation of antibodies specific for 
HLA-A2 MHC class I molecules restricted by tumor associated epitopes, such as the 
telomerase catalytic subunit (hTERT) epitope (117), the melanoma differentiation 
antigen gp100 (57) and viral epitopes such as the human T-cell lymphotrophic virus-1 
(HTLV-1) transcription factor Tax (49) and influenza matrix protein M1 (23). The 
molecules have since been used to visualize and quantify specific pMHCs on 
transfected cells, tumor cells, virally infected cells and antigen presenting cells. 
Interestingly, studies with TCR-like antibodies structures and comparisons between 
TCRs and TCR-like antibodies specific for the same pMHC ligand had shown that while 
these antibodies exhibit TCR-like specificity, they do not necessarily recognize the 
same contacts on the pMHC ligand (23, 126, 127, 134). Furthermore, they also show 
that unlike TCRs (12, 170), TCR-like antibodies do not have a conserved binding 
footprint on the pMHC ligand.  
 
In vitro Engineering of T Cell Receptors 
 The ability to engineer T cell receptors in vitro has allowed the production of 
stable soluble TCRs with enhanced binding affinities for their pMHC ligands (164). In 
addition, the use of adoptive T cell therapy with T cells of redirected antigen specificities 
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is a fast developing field (37, 48, 51, 178, 225). Co-receptors, i.e. CD4 and CD8 in 
helper and cytotoxic T cells respectively, aid in the binding of pMHC ligands and 
activation of the T cells (208). Thus, T cells transduced with genes of a normal, wild-
type TCR typically still require the appropriate co-receptors for activation. However, 
studies have shown that T cells transduced with engineered class I restricted TCRs 
above a particular affinity threshold (Kd values below 1 µM) exhibit co-receptor (CD8) 
independence (42, 43). This expands the application of TCR gene transfer by allowing 
the re-directed helper activities of CD4+ T cells to MHC class I restricted antigens. Thus 
engineering of T cell receptors for enhanced affinity will not only allow the use of soluble 
TCRs as tools for detection or directed delivery of therapeutic payloads, they could 
potentially expand the use of the receptors in adoptive T cell therapy.  
 The general strategy adopted for T cell engineering involves three steps; first, the 
identification and cloning of the α and β genes from a T cell clone with the desired 
specificity; second the generation and expression of mutant variants of the TCR in a 
display system; and finally the systematic, high-throughput screening of the TCR 
mutants for improved binding. As with soluble TCR expression, success in TCR 
engineering has been limited in part due to the relative instability of the TCR α and β 
chains, compared to the heavy and light chains of antibodies, such that not all TCRs are 
displayed efficiently. Nonetheless, phage, yeast and mammalian display systems have 
enabled the isolation of TCRs with enhanced affinity (41, 47, 94, 95, 118, 214).  
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Yeast display engineering 
 In the yeast display system, proteins of interest can be expressed as a fusion 
with the yeast mating protein Aga2p (25), allowing the proteins of interest to be localized 
on the surface of the yeast cells to facilitate subsequent analysis and screening. Gene 
sequences of mutants isolated after screening can be easily obtained by recovering 
plasmids, and sequencing. Yeast display has been successful in the engineering and 
isolation of lead antibodies (33, 66, 153). The first engineered TCR with over 100-fold 
improved affinity for the cognate pepMHC ligand was the mouse 2C TCR, engineered 
by yeast display (95). Along with the 2C TCR, the mouse class II MHC-specific TCR 
3.L2 and TCR Vβ domains (34, 59, 109, 212, 214) have all been engineered using 
yeast display for improved binding to their cognate pMHC ligand or superantigen, 
respectively. TCRs are heterodimeric molecules consisting of the α and β chains. 
However to avoid the difficulties in maintaining stable expressions of two separate 
chains in yeast cells, the 2C and 3.L2 TCRs were engineered by yeast display as a 
“single-chain” construct whereby only the variable domains of the α and β chains were 
expressed, with a peptide linker connecting the domains. However with the truncation of 
the TCR, the single-chain constructs and the Vβ domains were inherently unstable; to 
“stabilize” the domains, the genes were subjected to random mutagenesis across the 
entire construct to generate mutant libraries that could be screened by high-speed cell 
sorting for surface expression. Mutants with higher levels of surface expression were 
also capable of being expressed at higher levels in various expression systems, 
including E. coli, allowing the production of these soluble proteins for further studies and 
applications such as therapeutics or targeted delivery. 
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Figure 1.1. Immune receptors of the B cell and the T cell. (A) The B cell 
receptor consist of an membrane bound IgM associated with the Igα and Igβ 
signaling proteins. The T cell receptor is a heterodimeric protein consisting of 
the α chain and the β chain each made up of a single variable (V) and a single 
constrant (C) domain. The complex also consist of the CD3 protein made up of 
γ, δ, ε and ζ chains, and the CD4 or CD8 co-receptor. (B) The antibody is the 
soluble form of the BCR while TCRs are recombinantly expressed as a 
truncated receptor in soluble form. (C) Engineered single chain versions of the 
receptors consist of just the antigen specific domains fused via a flexible linker.  
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Figure 1.2. Structure of hepatitis B virion and genome. (A) Diagram of 
HBV virion. The virion has a diameter of about 42nm and consist of an 
icosahedral core encapsulating the HBV DNA genome and the polymerase 
protein, and an outer lipid envelope embedded with the S, M and L proteins. 
(B) Genomic organization of HBV. 4 mRNA transcripts are produced, the 3.5kb 
pre-genomic RNA that also contains the ORF for the pre-core, core and 
polymerase proteins; the 2.4kb and the 2.1kb mRNAs that produces the S, M 
and L proteins and the 0.7kb mRNA that is translated into the X protein 
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CHAPTER TWO 
 
CHARACTERIZATION OF T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR 
HEPATITIS B ANTIGENS 
 
Introduction 
 The complex between a viral peptide and a class I product of the major 
histocompatibility complex (pMHC) is a cell surface marker of an infected cell. Viral 
proteins produced in the infected cell are degraded by the proteasome, the resultant 
peptides are loaded onto MHC class I molecules in the endoplasmic reticulum, and the 
pMHC is transported to the plasma membrane for extracellular presentation (92). CD8+ 
T cells expressing a specific T cell receptor are able to recognize the viral pMHC. The 
binding process leads to activation of the T cell, resulting in the lysis of the infected cell 
and control of viral replication. The quantity and density of the specific pMHC molecules 
are factors that influence the immune response (105).  Thus, the ability to examine the 
presence and distribution of specific viral pMHC would benefit our understanding of viral 
infections and could inform decisions on anti-viral therapies.  
 Class I MHC molecules bind peptides of 8 to 10 amino acids in length. As virus 
genomes encode proteins that consist of a few thousand to tens of thousands of amino 
acids in total, the number of possible peptide sequences presented by the MHC class I 
molecule of the infected cell can be large. Yet interestingly, the number of immunogenic 
peptide sequences is small in comparison. This is partly due to the restrictions imposed 
by the nature of the MHC class I molecules themselves, as they require the peptides to 
have particular “anchor” residues for efficient binding. Among the immunogenic 
 30 
peptides, immunodominant epitopes are defined as peptides recognized by the most 
abundant T cell populations. Discovery and characterization of such peptides are areas 
of interest in viral infection research, such as with the hepatitis B virus, as they provide 
information about possible vaccines or other immune-based therapies. Two such 
immunodominant hepatitis B virus peptides are the Core18-27 and Env183-191 peptides, 
which are restricted by the HLA-A2 molecule, the most common class I allele in the 
human population. T cell clones specific for these pMHCs have also been isolated from 
patients. As the most abundant epitopes would also be the most desirable target for 
directed therapy, additional probes to study the distribution of these pMHC molecules 
would be useful.   
 Quantification of endogenously formed pMHC class I complexes has been 
achieved through various approaches (226). One approach correlates the amount of 
synthetic peptide required for T cell activity in comparison to activity with the infected 
cells; this approach is based on the assumption that the synthetic peptide is the same 
as the endogenously processed peptide. Also, the peptides (synthetic and endogenous) 
are assumed to be presented in the same conformations by the MHC moelcules, 
although it has been shown in a MHC class II system that differences can occur (150).  
Another more tedious approach involves elution of the peptides from the pMHC 
complexes of the infected cells, and purification of the peptides by chromatography; the 
purification and yields are followed by T cell activity assays, in comparison with a 
defined synthetic peptide (64, 90). This process is often unsuccessful due to the low 
levels of the endogenous peptide, compounded by the inconsistency and inefficiency of 
the peptide extraction process, thus limiting the practicality of this technique.  
 31 
Finally, more recent approaches have attempted to generate soluble binding 
probes with specificity for the pMHC, using the probes to detect the pMHC in situ. 
Accordingly, with the use of fluorescence-based detection techniques such as flow 
cytometry and microscopy, pMHC can be directly quantified on the cell membrane 
without complicated processing.  
 The natural receptor for the pMHC is the heterodimeric membrane bound T cell 
receptor (TCR). However, the inherent instability of these molecules in soluble form, 
and their low binding affinities for the pMHC, have complicated their use as a probe for 
detection (9, 169). Antibodies, on the other hand, can provide a source of soluble 
molecules with high affinities and specificities that have been used routinely in 
numerous research applications. Antibodies with TCR-like specificities have recently 
been isolated or engineered against numerous tumour-associated and viral epitopes 
(23, 57, 113, 117, 134, 139, 149), but to date they have not been generated against 
HBV related peptides. In this chapter, I describe the characterization of two monoclonal 
antibodies that have been isolated with TCR-like specificities for the two different HBV 
immunodominant epitopes, the Core18-27 (Core18/A2) and Env183-191 (Env183/A2) 
peptides restricted by the HLA-A2 class I molecule. I show that the antibodies are highly 
specific for their respective peptides in complex with the HLA-A2 class I molecules, 
specifically the HLA*A02:01 and HLA*A02:02 alleles and compared the fine specificity 
of the antibodies with the T cell clones that are specific for the same pMHCs. I also 
demonstrated several applications of the antibodies in the study of the quantity and 
distribution of the pMHCs. The antibodies were used to visualize pMHCs on the surface 
of cells and liver biopsy sections by microscopy. The antibodies were used to quantify 
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pMHCs on the surface of antigen presenting cells and its effect on the activation of T 
cell clones with the same specificities. Lastly, I utilized the C18/A2 antibody to examine 
the effect of interferons α and γ on the number of specific pMHC presented on the 
surface of HBV infected cells. 
 
Materials and Methods 
Generation of TCR-like antibodies 
 The TCR-like antibodies were previously generated by Konduru S.R. Sastry. In 
brief, inclusion bodies of the HLA-A201 MHC class I heavy chain and β2-microglobulin 
were expressed in Escherichia coli cells and refolded in vitro in the presence of excess 
peptides (HBV Core18-27 or Env183-191). Purification of refolded complexes was done 
using ion-exchange and size exclusion column chromatography and used in the 
immunization of BALB/C mice in a regime consisting 4 doses at 2-week intervals by 
interperitoneal injection of solutions consisting of 25µg of purified pMHC monomer and 
Freund's complete adjuvant (primary dose) or incomplete adjuvant (booster doses). 
Isolated splenocytes from immunized mice were fused with NS1 myeloma cells at a 1:1 
ratio to generate hybridoma cells. Supernatants of hybridoma were then collected and 
tested for specific binding. T2 cells pulsed with 1µM HBV Core18-27 or Env183-91 peptides 
were incubated with 50 µL of hybridoma supernatants and binding was detected 
with anti-mouse IgG Alexa Fluor 488 secondary antibodies. T2 cells pulsed with 
influenza M1 peptides were used as a control. Positively screened hybridoma cultures 
were subjected to rounds of limiting dilution and screening to identify single hybridoma 
clones. 
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Cell lines 
 T2 cells (ATCC CRL 1992) and EBV transformed B cell lines were cultured in 
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 20 mM HEPES, 
0.5 mM sodium pyruvate, minimal essential medium (MEM), nonessential amino acids, 
Glutamax, 5 µg/mL Plasmocin (InvivoGen), 100 U/mL penicillin, and 100 µg/mL 
streptomycin. HepG2 and HepG2 H1.3 cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 20 mM HEPES, 
0.5 mM sodium pyruvate, minimal essential medium, nonessential amino acids, 
Glutamax, 5 µg/mL Plasmocin (InvivoGen), 100 U/mL penicillin, and 100 µg/mL 
streptomycin. To boost HBV production, HepG2 H1.3 cells were transferred to Williams 
E medium supplemented with 5% FBS and in addition to the ingredients described 
above, 22 µg/mL hydrocortisone, 7 µg/mL inosine, 10 µg/mL insulin and 1% dimethyl 
sulfoxide. HBV-expressing HepG2-117 cells were cultured in the same culture media as 
mentioned above plus HBV expression is suppressed by 1 µg/mL doxycycline in 
HepG2-117 cells. HBV expression was boosted with the withdrawal of doxycycline from 
culture media along with the addition of 1% DMSO and 1000U/mL of IFN-γ.  
 
Detection of pMHC complexes on pulsed and HBV producing cells  
 The T2 cell line (ATCC CRL 1992) is a mutant cell line that lacks the transporter 
associated with antigen processing 1 (TAP1) and TAP2 genes, which allows the 
efficient loading of peptides onto nascent HLA chains while the HepG2 cell line is an 
HLA-A*0201+ hepatoma cell line (ATCC HB-8065). T2 and HepG2 cells were pulsed 
with peptides at the indicated concentrations at 4°C for 60mins before washing with 
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fluorescence-activated cell sorter (FACS) staining buffer (1% bovine serum albumin 
[BSA] in phosphate-buffered saline [PBS] with 0.01% sodium azide). Staining of the 
pulsed cells was done with the antibodies diluted in FACS buffer to the required 
concentrations in 50µL final volumes for at 4°C for 60mins. Cells were subsequently 
washed before incubating with 1µg/mL of fluorescence-conjugated anti-mouse IgG 
secondary antibody in 50 µL staining buffer at 4°C for 30mins. After further washing 
steps, cells were analysed with a BD FACSCanto (Becton, Dickinson and Co.) flow 
cytometer. Data acquired were further analysed by FlowJo (Tree Star). 
 
Surface plasmon resonance 
 Binding studies were carried out using the BIAcore™ 2000 (BIAcore AB). HLA-
A*0201 monomers presenting the Env183-191 peptide and Core18-27 were immobilized 
onto CM5 binding chips by amine coupling at pH 6.0. A titration of concentrations of the 
Core18/A2 and Env183/A2 antibodies were flowed over the pMHC ligands at a flow rate 
or 5µL/min. Measurements were done at 25°C in 20mM Tris pH 8.0. Kinetic binding 
parameters were determined using BIAevaluation software. 
 
Quantification of pMHC complexes 
 T2 cells pulsed with a titration of HBV Core18-27 or Env183-191 peptides were 
stained with the respective antibodies with TCR-like specificities as described above. 
The QIFI™ Kit (Dako) consisting of a range of beads with known numbers of IgG 
complexes was used as a standard for comparison. Antibody stained T2 pulsed cells 
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and analysed by flow cytometry. The number of pMHC complexes on the surface of the 
cells can be inferred by comparing the MFI observed against a standard curve 
generated from the MFI obtained from the analysis of the standard beads.  
 
HBV-specific CD8+ T cells degranulation assay 
 CD8+ T cells specific for the Core18-27 or Env183-191 HLA-A2 pMHC cells (80) were 
incubated with peptide-pulsed T2 cells with phycoerythrin conjugated anti-CD107 
antibody (BD Pharmingen) 37°C for 5 hours. Cells were then washed and stained with 
phycoerythrin-Cy7 conjugated anti-CD8 antibody at 4°C for 15mins before washing and 
analysis by flow cytometry.  
 
Visualization of pMHC complexes by fluorescence and confocal microscopy 
 HepG2 and HepG2 H1.3 cells were cultured on coverslips in media. Coverslips 
were then washed with PBS and fixed with 1% paraformaldehyde (PFA) at room 
temperature for 15 mins. Coverslips were then washed thoroughly with PBS and 
blocked with 5% goat serum at room temperature for 60 mins. Staining of the cells were 
done with 10ug/mL of Core18/A2 specific antibody at 4°C overnight. Coverslips were 
then washed and incubated with anti-mouse IgG-horseradish peroxidase (HRP) 
polymer (Dako) before performing the tyramide signal amplification according to 
manufacturer’s instructions using the Alexa Fluor 647-tyramide signal amplification kit 
(Invitrogen). Coverslips were then mounted using Antifade gold reagent containing 
DAPI (4′,6-diamidino-2-phenylindole) (Invitrogen) and images were captured either 
 36 
using the TissueFax (TissueGnostics) fluorescence microscope or the Nikon A1 
confocal laser microscope system.  
 
Results 
Specificity of TCR-like antibodies 
 The antibodies that recognize the HBV peptides Core18-27 and Env183-191 in 
complex with HLA-A2 MHC class I molecule were isolated by Konduru S.R. Sastry from 
mice separately immunized with the refolded pMHC complexes. A schematic 
representation of the production of the antibodies is shown in Figure 2.1. In summary, 
about 1500 and 2000 hybridomas were produced from mice immunized with the Core18-
27 HLA-A2 (Core18/A2) and Env183-191 (Env183/A2) HLA-A2 complexes, respectively. 
The majority of these did not secret antibodies that bound to the peptide-HLA-A2 
complexes, and of those that did, most were not peptide specific, as expected (Table 
2.1B). However, several of the antibodies did exhibit peptide specificity, and from these, 
a single hybridoma clone was selected for each peptide-HLA-A2 complex, and the 
antibodies were purified by chromatography from culture supernatant. These two 
antibodies were used for the studies presented in this chapter. 
 Hybridoma screening during the generation of the antibodies showed that the 
antibodies had specificity for their cognate ligand, but to further examine specificity and 
possible cross-reactivity, the antibodies were tested with a panel of known HLA-A2 
binding peptides including HBV peptides derived from the polymerase, X, envelope and 
core proteins, as well as other viruses and tumor associated antigens. Figure 2.2A 
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shows that both antibodies were highly specific for their respective peptide MHC and 
exhibit minimal if any cross-reactivity to the other HLA-A2 binding peptides.  
Next, the antibodies were tested for cross-reactivity with other MHC class I 
molecules. Several EBV transformed B cell lines expressing the natural allelic variants 
of the HLA-A2 Class I MHC HLA-A*02:01, -A*02:02, -A*02:03 and -A*02:06, along with 
cells that express two other serotypes; -A*11:01 and -A*24:02 were pulsed with 1µM of 
peptides before staining with the respective antibody. The antibodies showed cross-
reactivity with HLA-A*02:01 and -A*02:02 but minimal binding to the other MHC Class I 
complexes (Figure 2.2B). Although A*02:03 and A*02:06 share greater homology to 
A*02:01 and A*02:02 than A*11:01 and A*24:02 (Figures 2.2C,D), the mutations on the 
α2 domain helix in A*02:03 potentially affect the antibody recognition while the F9Y 
mutation in A*02:06, found on the beta sheet at the base of the peptide binding groove, 
could potentially affect the way the peptide is presented to the antibodies. 
 
Binding avidity of TCR-like antibodies 
 To determine the binding affinity of the antibodies for their respective pMHC 
ligands, two separate experiments were done. First, T2 cells pulsed with 1µM of Core18-
17 or Env183-191 peptides were stained with a titration of concentrations of the respective 
antibody as described in Materials and Methods and analyzed by flow cytometry. The 
mean fluorescent intensity of binding was plot against the concentrate of antibody used 
(Figure 2.3A). Binding kinetics were further analyzed by surface plasmon resonance 
(SPR). Soluble Core18/A2 and Env183/A2 pMHC complexes were refolded in vitro and 
immobilized to CM5 biosensor chips by amine coupling. Binding studies of the 
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antibodies to these immobilized pMHCs were then carried out with varying 
concentrations of antibodies. SPR measurements suggest that both antibodies had 
apparent KD values between 20-50nM (Figure 2.3B), indicating that both antibodies had 
relatively high affinities for the pMHC ligands. 
 
Fine specificities of TCR-like antibodies 
 TCRs and antibodies are structurally similar but recognize and bind their 
respective antigens in distinct manner. While TCR recognize their pMHC ligands in fixed 
diagonal orientations with respect to the MHC helices, studies to date suggest that 
antibodies recognize ligands with more variable docking orientations (23, 127, 169). 
Thus, with the availability of these two TCR-like antibodies, it is of interest to compare 
the possible footprints of these antibodies, over their respective pMHC complexes, with 
two TCRs with the same specificity. In addition, it would be useful to compare the 
peptide fine specificities of the antibodies and TCRs, to possibly understand aspects of 
the binding sites of these distinct molecules.  
To begin to examine these issues, peptide variants of the two HBV peptides with 
single amino acid substitutions in every position in the amino acid sequences of the 
peptides were generated. The ability of the antibodies to recognize and bind these 
peptide variants in complex with the HLA-A2 class I molecule were tested using T2 cells 
pulsed with 1µM of each peptide. Figure 2.4A shows the Core18/A2 antibody did not 
tolerate amino acid substitutions are position 22 and 23 while the binding of the 
Env183/A2 antibody was affected by substitutions at positions 187 and 189. T2 cells 
pulsed with the alanine peptide variants were also used in degranulation assays with 
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two monoclonal T cell lines that express TCRs that recognize the Core18/A2 and 
Env183/A2 complexes respectively. Activation of these cell lines was measured by the 
CD107 expression. Figure 2.4B shows the effect of the amino acid substitutions on the 
activation of the monoclonal T cell lines expressing TCRs that recognize the Core18/A2 
and Env183/A2 complexes respectively (Core18/A2 T cell activation data provided by 
Adam Gehring). Interestingly, similar to the antibody, activation of the Core18/A2 
specific T cell clone was most affected by positions 22 and 23. However, the Env183/A2 
specific T cell had a very different footprint or chemistry of binding compared to 
Env183/A2 antibody with positions 186 and 188 affecting binding most while positions 
187 and 189 were less important. Furthermore, it can be observed that T cell activation 
was affected by substitutions at more positions than antibody binding, although this 
could also be attributed to the inherent sensitivities of the T cell activation and antibody 
binding assays,  
 
TCR-like antibodies recognize endogenously processed and presented pMHC in HBV 
infected cells 
 Although the antibodies have so far been shown to be able to recognize and bind 
HBV peptide pulsed T2 cells, broader applications of these antibodies would be 
possible if they actually can be used to detect pMHC complexes produced by HBV-
infected hepatocytes (i.e. peptides from endogenously processed viral proteins). To do 
so, I utilized an HLA-A2+ human hepatoma cell line HepG2 and a derivative cell line 
known as HepG2-H1.3 (H1.3). H1.3 cells are HepG2 cells stably transfected with a 
plasmid containing 1.3-fold over-length HBV genome (186) and thus are able to express 
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all HBV proteins and to present on their surface HBV peptides-HLA-A2 complexes. 
Production of HBV proteins are stimulated by culturing in Williams media with 
supplements as described in Materials and Methods. Figure 2.5 shows that both 
antibodies are able to recognize and bind pMHC complexes formed endogenously in 
stimulated H1.3 cells. However, the quantity of specific pMHC complexes produced by 
the H1.3 cells is lower than peptide pulsed HepG2 cells, in part possibly due the 
observations that hepatocytes have inefficient antigen processing machinery (181). 
 
Visualization of pMHC complexes in pulsed cells and virus producing cell lines by 
confocal microscopy 
 The ability of the antibodies to recognize both exogenously pulsed and 
endogenously processed pMHCs was demonstrated by flow cytometric analyses. Next, 
I determined whether the antibodies could be used to visualize these pMHCs by 
microscopy. Adherent HepG2 and HepG2 H1.3 cells were cultured over coverslips. 
HepG2 cells were pulsed or left un-pulsed while H1.3 cells were stimulated for 
production of HBV proteins. The coverslips were then fixed and stained with the 
respective antibodies. A tyramide signal amplification kit was used to visualize the 
antibody staining. Coverslips were mounted in reagent that contained DAPI for the 
visualization of nuclei. Figure 2.6A and Figure 2.7A show the visualization of the stained 
cells under a fluorescent microscope using the Core18/A2 antibody and Env183/A2 
antibody respectively.  
Pulsed and un-pulsed HepG2 cells were further analysed by confocal 
microscopy, using the Core18/A2 antibody and an antibody specific for the MHC class I 
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subunit β2-microglobulin (β2m). As shown in Figure 2.6B, staining of the Core18/A2 
antibody co-localized with that of an antibody against β2m, providing further evidence 
that the antibody was specifically binding the pMHC on the surface of the pulsed HepG2 
cells.  
Immunohistochemistry is often done on patient biopsies during diagnosis. To 
determine if the antibodies might be amenable to this application, cryostat sections of 
liver biopsy specimens from chronic hepatitis B patients were stained with the 
Env183/A2 antibody (data provided by collaborators from Barts and the London School 
of Medicine, UK) and analysed using the EnVision Plus mouse HRP polymer kit. Figure 
2.7B shows that the antibody specifically stained naturally infected cells from patients 
that were antigen and HLA-A2+ but not specimens from antigen negative or HLA-A2- 
patients.  
 Intracellular Toll-like receptors such as TLRs -3, 7, 8 and 9 are innate immune 
receptors that detect the presence of viruses by the recognizing viral DNA or RNA in the 
endosomal compartment and initiate anti-viral responses including the production of 
type I interferons (24, 96). However, the hepatitis B virus has evolved strategies to 
evade detection by TLRs (179, 218). Thus the option to stimulate Toll-like receptors 
signalling in infected cells by the directed delivery of TLR agonists provides a possible 
therapeutic measure to aid in the control of HBV replication in the infected cell. 
Antibodies are known to internalize by receptor-mediated endocytosis. To examine if 
the TCR-like antibodies were similarly internalized in HBV producing HepG2 cells after 
binding their pMHC targets, Alexa-488 fluorophores conjugated Env183/A2 antibodies 
were first prepared by Zenon labelling (Invitrogen). Target cells grown on cover slips 
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were first stained with the conjugated antibodies and a membrane dye as described in 
Materials and Methods and then incubated in culture media at 37°C. Coverslips were 
then washed and further stained with Dil red for the plasma membrane or LysoTracker 
red (Invitrogen) for lysosomes before mounting and analysis by confocal microscopy. 
Figure 2.7C shows that surface staining of the antibody co-localized with the membrane 
dye Dil red at the beginning of the incubation but diminished after 4hrs and appear to be 
internalized due to the loss of co-localization with Dil red staining. At 16hrs, cells were 
stained for lysosomes using LysoTracker red and in Figure 2.7D, the antibodies that 
had internalized are observed to be located in the lysosomes, evidenced by the co-
localization of the Alexa-488 fluorophores and the LysoTracker red staining 
(internalization data provided by Konduru Sastry).  
 
Quantifying pMHC complexes required for T cell activation on pulsed cells  
 The activation of CD8+ T cells depends on the interaction of co-stimulatory 
molecules, the affinity of the TCR for the pMHC, and the density of the peptide-class I 
MHC complex (105). The number of pMHC required for the activation of T cells has 
been observed to vary from several thousands to as low as three per target cell, 
depending on the pMHC-TCR pair (105, 192). Here, I utilized the TCR-like antibodies to 
investigate the sensitivities of two T cell clones that are also specific for the Core18/A2 
and Env183/A2 pMHCs (Figure 2.8). Quantification of the number of complexes on the 
surface of pulsed T2 cells was done by comparing the mean fluorescence intensity 
(MFI) of the same fluorophore conjugated-secondary antibody bound to TCR-like 
antibody associated on the surface of pulsed cells with those bound to standard beads 
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conjugated with known number of mouse IgG (Dako QIFI™ kit). T2 cells were first 
pulsed with peptide concentrations ranging from 1fM to 1µM and then stained with 
saturating concentrations of TCR-like antibodies as described in Material and Methods. 
These stained cells and the standard beads were then incubated with the same 
secondary antibodies and finally analysed by flow cytometry. A standard curve 
correlating the number of IgG on each population of bead provided in the kit with the 
MFI of the staining by the secondary antibody was determined as specified by 
manufacturer’s instruction and the number of pMHC complexes on each population of 
pulsed T2 cells was determined from this curve. Similarly pulsed T2 cells were used in 
CD8 T cell degranulation assays to determine the levels of T cell activation. Pulsed T2 
cells were co-incubated with the respective CD8 T cell clones with phycoerythrin 
conjugated anti-CD107 antibody for 5 hours at 37°C. After incubation, cells were 
collected and stained phycoerythrin-Cy7 conjugated anti-CD8 antibody, washed and 
analysed by flow cytometry. Figure 2.8 summarizes the results from these assays. 
While T cell activation was detected when peptide concentrations used for pulsing was 
as low as 10fM, TCR-like antibody binding was detectable only when T2 cells were 
pulsed with at least 10pM of peptides. Quantification using the standard beads showed 
that antigen presenting cells with 50 or less number of complexes were able to stimulate 
T cells (Figure 2.8B). Interestingly, for 50% of Env183/A2 specific T cell clones to be 
activated, a pMHC density of between 50-200 complexes per cell was required, but for 
the same level of activation of C18/A2 specific T cells, the number of complexes 
required is much greater at between 1000 to 6000 complexes, reflecting the difference 
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in sensitivity of the two different T cell clones (T cell degranulation data provided by 
Zack Ho and Adam Gehring). 
 
Effect of interferons α and γ on antigen presentation  
 Interferons (IFN) play a major role in the control of Hepatitis B virus infection. 
Both type I and II IFN produced endogenously have been correlated with efficient 
control and clearance of HBV; in addition, IFN-α is now a standard therapeutic 
treatment for chronic infections. Studies have suggested that the anti-viral effect of 
interferons may be due to their inhibitory effect on viral gene expression (87, 200). This 
reduction in gene expression may result in the reduction of immune recognition due to 
the lower amount of viral antigens available for presentation. However, interferons are 
also known to be potent upregulators of class I MHC molecules expression (26, 195). 
Thus, it was of interest to study the effect of interferons on specific pMHC presentation 
on infected cells. Utilizing the Core18/A2 TCR-like antibody as the detection reagent, I 
analysed the levels of the Core18/A2 pMHC on the surface of the HepG2 H1.3 cells, 
HepG2 cells that are endogenously expressing HBV proteins, following treatment with 
IFN-α and IFN-γ (Figure 2.9). H1.3 cells were treated with three different dosages of 
IFN-α and-γ at 10U/mL, 100U/mL and 1000U/mL. Treated cells were harvested at 0hrs, 
6hrs, 12hrs, 24hrs and 48hrs after treatment and stained with an anti-HLA-A2 antibody 
and the Core18/A2 antibody as described in Materials and Methods. Figure 2.9A shows 
that both IFN-α and-γ on HepG2 cells upregulated HLA-A2 molecules in a dose 
dependent manner, with effects lasting even after 48hours. Similarly, in Figure 2.9B, 
IFN-α and-γ upregulated HLA-A2 expression in H1.3 cells as soon as 6hrs and 
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continued to do so after 48hrs of treatment. Figure 2.8C shows the corresponding levels 
of Core18/A2 pMHC. The levels of Core18/A2 pMHC increased after 6hrs, 
correspondingly to the increase in HLA-A2 expression. However, unlike HLA-A2 
expression, the levels of Core18/A2 pMHC peaked after 6hrs and plateaued and even 
showed slight decrease with further incubation. This suggests that the levels of core 
antigen available for presentation had becoming limiting, possibly due to a decrease in 
viral gene expression, as described by others (87, 200). 
 
Discussion 
 The ability to study complexes of HBV peptides with MHC products has been 
limited resulting in a lack of information on how the quantitative and distributive features 
of HBV pMHC on infected cells affects immune responses. To address this, two 
monoclonal murine antibodies specific for the immunodominant epitopes Core18-27 and 
Env183-191 peptides, restricted by the class I MHC molecule HLA-A2 were isolated in the 
lab. Here I show that not only are these antibodies specific for their respective pMHC 
ligands, but they have high sensitivity and are able to recognize both exogenously and 
endogenously formed pMHC complexes. The latter two points are of particular 
significance because of low levels of HLA class I molecule expression and poor antigen-
processing activity of hepatocytes (79, 181). I also show here that these antibodies can 
be used in various applications involving HBV-related studies.  
 As a diagnostic tool, the antibodies exhibited excellent specificity and sensitivity 
not only with pulsed cells and transduced cell lines; they were also able to recognize 
pMHC complexes on naturally HBV-infected hepatocytes and be used in tissue biopsy 
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staining (Figure 2.7B). In addition to this, the ability to visualize pMHC on the surface of 
cells allows us to not only understand the distribution of specific pMHCs at the tissue 
level, but also at the cellular level. These findings provide some additional 
understanding of viral pMHC recognition and T cell activation, for example in the context 
of the minimal requirements for immunological synapse formation. TCR clustering has 
been considered a pre-requisite for signalling and subsequent T cell activation (184), 
facilitating phosphorylation between the CD3 tails and associated protein tyrosine 
kinases for the initiation of intracellular kinase cascade (120). Studies have suggested 
that TCR clusters are pre-formed and exist even in resting cells while others proposed 
some degree of valency of interaction between the pMHC and the TCR had to be 
formed within close contact regions between the antigen presenting cell and the T cell in 
order for activation to occur (5, 209). Regardless of the model proposed, the pMHC 
presents a myriad of peptides on their surface MHC molecules and for the rare specific 
endogenous pMHCs to be able to promote TCR aggregation in order for activation to 
occur, there is a strong suggestion of a similar arrangement of clustered pMHC on the 
APC membrane. Furthermore, previous studies, along with my observations (Figure 
2.8), had shown that very small numbers of pMHC complexes are required for T cell 
activation (105, 192). Here, I have demonstrated the applications of the antibodies both 
in the quantification of pMHCs and visualization in fluorescence-microscopy. These 
potentially allow further studies with infected hepatocytes that would definitely be able to 
provide us with a better insight into both the distribution of endogenously generated 
pMHC on naturally infected cells and its on T cell recognition and activation.  
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 The antibodies also allow me to analyze the distribution and quantity of two 
immunodominant epitopes. These epitopes are recognized by the majority of CD8+ T 
cells in infected patients (17, 124, 141) but such T cells are usually absent or in a 
tolerant state in chronic patients (161, 215). T cell clones that are specific for these 
immunodominant epitopes from infected patients have been previously isolated and I 
show, with the use of the antibodies, the high sensitivity avidity of these T cell clones for 
the pMHC complexes. More importantly, the T cell receptors of these T cell clones had 
been cloned and introduced into primary lymphocytes of chronic patients retrovirally 
(80). Not only were the TCR transduced T cells able to express the appropriate αβ TCR 
pair, they were able to recognize and lyse exogenously peptide pulsed hepatocytes and 
cell lines endogenously expressing HBV proteins, in vitro and in vivo. This study 
demonstrates the potential of adoptive transfer of TCR re-directed T cells for the 
treatment of HBV related hepatocellular carcinoma. In tandem with this notion, the 
antibodies specific for the same pMHCs can be used prior to administration of treatment 
in the diagnosis of patients. As shown in Figure 2.7B, biopsy analysis of specimens 
obtained from patients would facilitate informed decisions on the use of or the 
identification of the best HBV peptide-MHC target before proceeding with re-directed T 
cell therapy. The ability to quantify and compare the levels of HBV pMHC presented to 
the CD8 T cells, e.g. levels Env183/A2 pMHC and Core18/A2 allows for more 
personalized treatment with optimal efficacy. However notably TCR-like antibodies and 
TCRs may have different chemistries of binding for the same pMHC complex, e.g. the 
Env183/A2 antibody and the T cell clone and as shown by others (23, 99, 127, 134), 
thus the fine specificities of these antibodies have to be taken into consideration.  
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 The use of these antibodies in the directed delivery of IFN-α in the form of fusion 
proteins had been demonstrated (102). However the evidence of internalization of the 
Env183/A2 specific antibody (Figure 2.7D) opens up the possibility of directed delivery 
of payloads such as Toll-like receptor agonists targeted at the endosomal TLRs -3, 7, 8 
and 9.  Intracellular TLRs function primarily to detect viruses with nucleic acids as 
ligands, however as the hepatitis B virus has evolved to evade detection by adopting a 
replication strategy whereby amplification of the viral genome occurs only within the 
capsids and the nucleus (179, 219). The ability to stimulate TLR signalling in infected 
cells would lead to the induction of genes involved in anti-viral responses including the 
production of type I interferons (24, 96). Type I interferons, IFN-α and IFN-β, are 
secreted by the virus-infected cells while type II, or IFN-γ is secreted by immune cells 
such as the CD4+ Th1 and CD8+ T cells. Both groups of interferons play vital roles in 
anti-viral immunity; IFN-γ signalling itself affects more than 200 genes involved in 
various aspects of immune responses (26, 171). The suppressive effect of IFN-α on 
HBV replication has been studied extensively; with groups showing that one of the key 
effects is the downregulation viral protein expression (16, 87, 155, 200), leading to it 
being sanctioned for use as a therapeutic drug for chronic HBV. One function in 
common between the two interferons is their effects on class I antigen presentation. 
Both interferons upregulate the expression of MHC class I molecules while IFN-γ, in 
addition, also upregulates the expression of the transporter associated with antigen 
processing molecules (TAP1 and 2), tapasin, β-subunits and activator (PA28) of the 
proteasome; all are vital factors in antigen processing in the class I antigen presentation 
pathway (26). In concurrence with the former, I had demonstrated that both IFN-α and 
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IFN-γ are able to upregulate the expression of the HLA-A2 class I molecule in both 
HepG2 and HepG2 H1.3 cells that are expressing HBV. Guidotti et al had shown that 
IFN-α is able to downregulate HBV gene expression in vivo, while Tur-Kaspa et al 
presented evidence suggesting IFN-α reduced HBV gene transcription via the HBV 
enhancer (87, 200). Here, I show that in HepG2 cells expressing HBV proteins, 
treatment of both IFN-α and IFN-γ resulted in increased numbers of specific HBV 
Core18/A2 complexes on the surface of the cells. Hepatocytes express low levels of 
class I molecules, thus my observations would suggest that the poor expression of 
these molecules may be the limiting factor to the presentation of HBV specific pMHC on 
the surface of infected cells and with treatment of interferons, more such pMHC can be 
generated and presented, allowing infected cells to be more visible to T cells and 
facilitating the induction of anti-viral immune responses. 
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Figure 2.1. Generation of monoclonal antibody with TCR-like specificity 
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Figure 2.2. Specificity of TCR like antibodies that recognize 2 hepatitis B 
virus peptides restricted by the HLA-A2 MHC molecule. (A) Both Core18/
A2 antibody and Env183/A2 antibody showed specificity for their cognate 
pMHC ligand and no cross-reactivity for the other pMHC tested. (B) EBV 
immortalized B cell lines positive for different HLA-A2 subtypes and 2 other 
HLA-A allomorphs were pulsed with 1uM of either the Core18-27 or Env183-191 
peptides and stained with the respective antibody. Both antibody recognize 
their cognate peptides presented by HLA-A*02:01 and HLA-A*02:02 subtypes 
but not the other MHC class I molecules. Amino acids positions that differ from 
HLA-A*02:01 (grey) are indicated for (C) A*02:02 (red and yellow), A*02:03 
(green and yellow), A*02:06 (blue) and (D) HLA-A*11:01 (red and yellow) and 
A*24:02 (blue and yellow). 
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Figure 2.3. Measuring the dissociation constant (KD) of the TCR like 
antibodies. (A) T2 cells were pulsed with 1µM of either the Core18-27 or the 
Env183-191 peptide and stained with a titration of the respective TCR like 
antibody. (B) Binding kinetics were further analyzed by surface plasmon 
resonance. Titration of antibodies were flowed over Core18/A2 or Env183/A2 
pMHC immobilized on the surface of sensor chips and the rates of binding and 
dissociation were used in the calculation of the respective dissociation 
constant KD. 
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Figure 2.4. Comparison of fine specificity of TCR like antibodies and 
respective T cell receptors. Single position alanine substitutions were made 
at every position of the Core18-27 and Env183-191 peptides. (A) T2 cells pulsed 
with each peptide variant were stained with the respective TCR like antibody. 
Substitutions at positions 22 and 23 affected Core18/A2 antibody binding while 
positions 187 and 189 affected Env183/A2 antibody binding. (B) The same 
peptide variants were used in T cell activation assays with T cell clones 
specific for the same peptide epitopes. (C) Comparison of positions that 
significantly affected T cell activation or the respective TCR-like antibody 
binding. 
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Figure 2.5. TCR like antibodies recognize and bind both exogenously 
pulsed and endogenously process pMHC complexes. HLA-A2+ HepG2 
H1.3 cells that express HBV proteins and thus present HBV viral pMHCs on 
their cell surface were stained with either (A) Core18/A2 antibody or the (B) 
Env183/A2 antibody. HepG2 cells pulsed with exogenous the Core18-27 and 
Env183-191 peptides were also stained with the the respective antibodies 
showing that both antibodies are able to recognize and bind endogenous and 
exogenously formed pMHC complexes. 
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Figure 2.6. Visualization of endogenously processed and exogenously 
pulsed Core18-27 pMHC on the surface of cells. (A) HepG2 H1.3 cells, 
unpulsed and 1µM Core18-27 peptide pulsed HepG2 cells were stained with the 
Core18/A2 antibody and visualized by fluorescent microscopy. (B) Unpulsed 
and pulsed HepG2 cells were co-stained with the Core18/A2 antibody and an 
anti-β2m antibody and visualized by confocal microscopy. Co-localization of 
anti-β2m antibody and Core18/A2 antibody staining shows that the TCR like 
antibody was specific for the pMHC complexes. 
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Figure 2.7. Visualization of Env183-191 pMHC on the surface of infected 
cells and internalization of Env183/A2 antibody. (A) HepG2-117 cell lines 
that express HBV proteins were stained Env183/A2 antibody or and isotype 
control antibody and visualized by fluorescent microscopy. (B) Liver biopsy 
sect ions were stained wi th Env183/A2 ant ibody detected by 
immunohistochemistry. (C) Env183/A2 bound to the surface of HepG2-117 
cells were observed to internalized after 4hr incubation at 37°C. (D) 
Fluorescently conjugated Env183/A2 co-localized with lysosome staining after 
16hr incubation.  
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Figure 2.8. Quantifying pMHC complexes required for T cell activation on 
pulsed cells. T2 cells were pulsed with (A) Core18-27 and (B) Env183-191 peptide 
concentrations ranging from 1fM to 1µM and stained with the respective 
antibody or used for T cell degranulation assay with T cell clones specific for 
the respective pMHC. Number of specific HBV pMHC complexes presented 
on the surface of the T2 cells were further quantitated using the Dako QIFI™ 
kit and correlated with the corresponding level of T cell activation.  
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Figure 2.9. Effect of interferons alpha and gamma on the presentation of 
specific pMHCs. (A) HepG2 cells were treated with three concentrations of 
IFN-α or IFN-γ, and levels of HLA-A2 were probed at three time points 0hrs, 
12 and 48 hours after treatment by staining with an anti-HLA-A2 antibody. (B) 
HepG2 H1.3 cells were similarly treated with three different concentrations of 
interferons and HLA-A2 levels were detected 0, 6, 12, 24 and 48 hours after 
incubation. (C) Levels of specific Core18-27 HLA-A2 complexes were also 
probed at the same time points as (B) using the Core18/A2 antibody. 
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CHAPTER THREE 
 
COMPARISON OF A SOLUBLE T CELL RECEPTOR AND A T CELL RECEPTOR-
LIKE ANTIBODY SPECIFIC FOR HEPATITIS B/HLA-A2 
 
Introduction 
 Antibodies and T cell receptors (TCRs) represent two distinct classes of immune 
molecules that the adaptive immune system in mammals has evolved to recognize 
foreign pathogens. Whereas antibodies can function as soluble molecules, TCRs are 
found only as membrane bound receptors (129). Furthermore, while antibodies are able 
to recognize antigens alone, often as linear or conformational epitopes of a polypeptide, 
TCR recognition invariably requires the antigenic peptide to be presented by a major 
histocompatibility complex (MHC) product on the cell surface (55). For example, 
peptide-MHC (pMHC) complexes are formed in virus-infected cells when processed 
viral proteins are loaded onto class I MHCs and delivered to the cell surface (154). This 
enables infected cells to be recognized, typically by a CD8+ T cell, resulting, ideally, in 
activation of the T cell, destruction of the target cell, and clearance of the virus (182). In 
hepatitis B virus (HBV) infection, which still poses a global health problem despite the 
availability of an effective prophylactic vaccine, CD8+ cytotoxic T lymphocytes (CTLs) 
play a crucial role in the antiviral response (21). Effective control of HBV relies on robust 
CTL responses, and CD8+ T cell dysfunction is associated with chronic infection, which 
in turn carries the risk of complications such as hepatocellular carcinoma.  
The ability to activate CTLs and the magnitude of CTL responses correlates with 
the levels and density of pMHC presented by HBV-infected cells (79). This has raised 
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an interest to both visualize the presented antigens on the surface of infected 
hepatocytes, and to generate molecular entities that enable the targeted delivery of 
pharmaceutical or immunomodulatory compounds (102, 172). A promising approach 
uses monoclonal antibodies (mAbs) with TCR-like specificities for distinct pMHC 
products, which attain affinities higher than normal TCRs (139, 149, 172). For such 
novel TCR-like mAbs, however, it remains important to individually assess whether they 
exhibit the same specificity as the cognate TCRs (76, 130). Structural studies already 
demonstrated that the docking position can differ from the conventional TCR, exhibiting 
interactions predominantly with the MHC, thus affecting peptide specificity (99). In 
addition, TCR-like mAbs are often raised in non-human species (e.g. mouse, rat or 
rabbit) and require subsequent transformation into human chimeras; a process known 
as “antibody humanization”, to be of therapeutic value. Because such mAbs have not 
been selected in vivo in the target species, cross-reactivity with self-antigens can also 
formally not be ruled out. 
An alternative strategy employs multivalent soluble TCRs to target antigens 
presented on the cell surface (9, 115), analogously to probing clonotypically expressed 
TCRs with oligomeric pMHC molecules, which are routinely used for the identification 
and characterization of virus-specific CTLs (6, 54). For successful implementation, 
however, several technical limitations need to be addressed. First, the expression and 
production of soluble TCRs is often problematic (169). Second, the affinities of TCRs 
are normally in the micromolar range, making detection of pMHC on cell surfaces with a 
soluble TCR probe difficult (132). Third, while the TCR is expressed on T cells at a 
uniform, relatively high density (about 50,000 molecules per cell; (189)) the number of 
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naturally processed antigenic pMHC complexes per cell is thought to be low, in the 
range of 10 to 1000 (226). To overcome these challenges, soluble TCRs have been 
recombinantly produced in various systems, such as insect cells (77) and E. coli (30, 
56, 75, 175). The low affinities of the monomeric TCRs have been enhanced both by 
oligomerization (9, 115, 143, 190, 230), and by directed evolution in either yeast or 
phage display systems (95, 118).  
In an effort to develop novel protein constructs for diagnostic and therapeutic 
application in the context of HBV, we generated a soluble form of an αβ T cell receptor 
isolated from an HLA-A*02:01 restricted CD8+ T cell clone specific for the immune-
dominant Env183-191 epitope (Env183/A2) of the HBV envelope protein. We show that 
the soluble TCR is both functional and highly peptide-specific using a multivalent, bead-
based assay that we developed as a novel platform for probing TCR:pMHC interactions. 
Using this assay, we compared the Env183-191 peptide fine-specificity of both the TCR 
and a monoclonal antibody previously isolated to recognize the same Env183-191/HLA-
A*02:01 (172). Finally, we established that the surface density of HLA complexes is a 
critical factor when TCR multimers and TCR-like mAbs are employed to detect MHC-
presented peptide antigens. 
 
Materials and Methods 
Cloning of TCR α and β chains 
 The Vα34 and Vβ28 Env183/A2 specific heterodimeric TCR was previously 
isolated from a T cell clone (80). Each chain was truncated, the α chain after Ser202 
and the β chain after Asp243, and cloned into pET28a expression vectors separately by 
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PCR using 5’ primers containing an NcoI restriction enzyme site that also contains the 
ATG start codon and 3’ primers that contains the stop codons and an XhoI restriction 
enzyme site. A disulfide bond was introduced by mutating residues Thr48 of the α-chain 
constant domain and Ser57 of the β-chain constant domain into Cys residues (as 
described previously (30)). In addition, an unpaired Cys75 of the β-chain constant 
domain was mutated to a serine to facilitate the specific pairing of the introduced Cys 
residues. A biotinylation motif was added to the C-terminal end of the β-chain to 
facilitate tetramerization with streptavidin 
  
Expression of TCR chains 
 The TCR chains were separately expressed in Rosetta™ Competent Escherichia 
coli cells (Novagen). Inclusion bodies were harvested from cells lysed by sonication and 
washed using washing buffer (50mM Tris, 100mM NaCl, 0.5% Triton X-100, 1mM 
EDTA, 0.1% sodium azide). 10mg/L of biotin was added during induction to the β chain 
expression cultures to facilitate in vivo biotinylation. Inclusion pellets were then 
dissolved completely in urea solution (8M urea, 25mM MES, 10mM EDTA, 0.1mM DTT, 
pH 6.0). Solubilized inclusion bodies were quantitated by Bradford assay (Biorad, 
Richmond, California) and stored at -80°C.  
 
Refolding and purification of refolded TCRs 
 The soluble TCR was refolded by rapidly diluting aliquots of 10mg of each chain 
in 1 litre of refold buffer (100mM Tris pH 8.0, 400mM L-Arg HCl, 2mM EDTA, 5mM 
reduced glutathione, 50mM oxidized glutathione) supplemented with a tablet of 
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cOmplete ULTRA protease inhibitor cocktail (Roche Applied Science). Two further 
injections of each inclusion bodies 8hrs apart yielded a final concentration of 60mg/mL 
total protein. The refolded protein was concentrated using a Vivaflow 50 crossflow 
cassette (Sartorius Biotech) and dialyzed twice into 2.5 litres of 20mM Tris pH 8.0 
overnight. Enzymatic biotinylation was carried out according to manufacturer’s 
instructions using BirA biotin ligase (Avidity). Purification of biotinylated TCRs was 
carried out by size exclusion chromatography (HiPrep 16/60 Sephacryl S200) followed 
by anion exchange chromatography (MonoQ 5/50 GL) using an AktaFPLC system. 
Fractions containing refolded heterodimeric TCRs were identified by SDS-PAGE. 
Biotinylation of purified refolded TCR was probed by gel shift assay whereby refolded 
TCR prepared in non-reducing SDS-PAGE loading buffer were incubated with excess 
streptavidin at room temperature (RT) for 15mins before SDS-PAGE analysis. 
 
Multimerization of refolded TCRs 
 Soluble TCRs were tetramerized by the addition of allophycocyanin (APC) 
conjugated-streptavidin (Invitrogen) to the monomers to a final volume of 1:4 
respectively. The total amount of streptavidin-APC required was divided into 5 aliquots 
and added to TCR monomers in 30mins interval. TCR tetramers were then stored at 
4°C and used within a month. 
 
TCR-like antibody 
 A mouse monoclonal antibody specific for the HLA-A*02:01-restricted Env183-191 
epitope was previously generated (172). Antibodies were purified from the supernatant 
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of the hybridoma culture using a protein G-agarose column, concentrated and quantified 
by Bradford Assay (Biorad, Richmond, California). 
 
Peptide-MHC conjugated beads assay 
 Recombinant HLA-A*02:01 MHC was expressed, refolded with the conditional 
ligand GILGFVF-J-L, biotinylated and purified as previously described (167, 199). UV-
mediated peptide exchange of these cages pMHC with the required peptides was 
performed as reported (11, 44, 167, 199). Fluorescent streptavidin-coated yellow 
particles kits (Spherotech SVFA-2552-6K and SVFB-2552-6K), and non-fluorescent 
streptavidin-coated particles (Spherotech SVP-30-5) were used to capture the pMHC. 
Beads were pre-incubated with 200µL of blocking buffer (2% BSA in PBS) for 30mins 
with shaking followed by incubation in excess of pMHC for 1hr with shaking. All 
incubations were carried out at RT. For the titration of pMHC loaded onto the beads, 4 
fold dilutions of the pMHC were done in blocking buffer before conjugation. Conjugated 
beads were washed with blocking buffer and subsequently stained with TCR tetramers 
of TCR-like antibodies. Staining of the conjugated beads was done at RT with shaking 
for 30mins before washing with blocking buffer and fixed with 1% paraformaldehyde in 
PBS before flow cytometry analysis. Secondary staining of the TCR-like antibody with 
an APC-conjugated goat anti-mouse antibody (Invitrogen) was done at RT with shaking 
for 20mins. Acquisition was done on an LSR-II or FACSCanto flow cytometer (Becton 
Dickinson) and data analysis was done off-line with FlowJo software (Tree Star) and 
GraphPad Prism software (GraphPad). 
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Cell culture and staining 
 T2 cells (ATCC CRL 1992) and EBO-PreS2 cells were cultured in RPMI 1640 
medium while HepG2.2.15 cells were cultured in Dulbecco’s modified Eagle’s medium, 
both supplemented with 10% fetal bovine serum (FBS), 20 mM HEPES, 0.5 mM sodium 
pyruvate, minimal essential medium (MEM), nonessential amino acids, Glutamax, 
5µg/mL Plasmocin (InvivoGen), 100 U/mL penicillin, and 100µg/mL streptomycin. Cells 
were treated with 100U/mL IFN-γ (R&D systems) for 24hrs before washing and pulsing. 
Cells were pulsed with 1µM or 10µM final concentration of peptides at RT before 
staining. Washing and staining were done in flow cytometry buffer (1% BSA, 0.01% 
sodium azide, in PBS). Cells were stained with 1ug/mL of Env183/A2 antibody or TCR 
tetramer unless otherwise stated at RT for 30mins with shaking. Secondary detection of 
TCR-like antibody was done with an APC conjugated goat anti-mouse antibody 
(Invitrogen). 
 
Surface plasmon resonance 
 Binding studies were carried out using the BIAcore™ 3000 (BIAcore AB, GE 
Healthcare). HLA-A*02:01 monomers presenting either the Env183-191 or Core18-27 
(control) peptide were immobilized onto CM5 sensor chips by standard amine coupling 
procedure. Briefly, the surface was activated for 5 min with 1:1 mixture of 0.2 M N-ethyl-
N’-[3-(diethylamino)propyl]carbodiimide (EDC) and 50 mM N-hydroxysuccinimide 
(NHS). The HLA complex, pre-diluted into 10 mM sodium acetate at pH 6.0, was then 
injected across the activated surface at 10 µL/min. The surface was finally blocked with 
by injection of 1 M ethanolamine at pH 8.5 for 7 min. Kinetic measurements were 
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performed in running buffer (50mM Tris, 150mM NaCl, pH7.0) at 30 µL/min at 25oC. 
TCR-tetramers (in 3-fold serial dilutions; 0.12, 0.37, 1.1, 3.3, 10 µM) were flowed over 
the immobilised HLA for 2 min and then allowed to dissociate for 30 min. The surface 
was regenerated with a 0.5 min pulse injection of 1:1000 phosphoric acid and stabilized 
with buffer for another 2 min before the next cycle. Binding responses were corrected 
against a control flow cell and a buffer cycle. Corrected responses were fit to a simple 
1:1 bimolecular interaction model. 
 
Structural modeling 
 The Env183-191 peptide was modeled into the Tax-HLA-A*02:01 (PDB-ID:1DUZ) 
using the Rosetta Backrub program (http://kortemmelab.ucsf.edu) (183). Figures were 
made using Pymol (DeLano Scientific Research LLC). 
 
Results 
Producing soluble Env183-191 peptide/HLA-A*02:01-specific TCR tetramers 
The genes encoding the extracellular regions of the α and β chains of the 
Env183/A2 TCR (80), with an additional cysteine introduced in each C region (30), were 
cloned into pET28a vectors and the proteins were expressed in E. coli as inclusion 
bodies. The soluble α and β chains have predicted molecular weights of ~23kDa and 
~28kDa, respectively. Equal amounts of inclusion bodies were combined under high 
dilution, and the concentrated solution was subjected to size exclusion chromatography 
(Fig. 3.1A).  A peak corresponding to the expected size of the heterodimeric TCR 
(~51kDa) was subjected to anion exchange chromatography (Fig. 3.1B). Fractions 
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corresponding to observed peaks P1 and P2 were pooled, concentrated and analyzed 
by SDS-PAGE under reducing and non-reducing conditions (Fig. 3.2A). P1 appeared to 
contain predominantly β chain presumably representing soluble non-disufide linked β 
chain refolded monomers. The increased electrophoretic mobility under non-reducing 
SDS-PAGE of this fraction, compared to the inclusion body preparation, we attribute to 
intramolecular disulfide bonding. In contrast, P2 had the anticipated equal stoichiometry 
of α and β chain, corresponding to the disulfide-linked αβ heterodimer. All subsequent 
studies were performed with this complex. To generate multivalent forms of the TCR, a 
BirA biotin tag was included at the C terminus of the β chain. To assess if the purified 
protein (P2) had been biotinylated during recombinant expression, gel shift analysis was 
performed by incubation with strepavidin (Fig. 3.2B). This showed that the majority of 
the product “gel-shifted” which is indicative of biotinylation. Fluorescent TCR tetramers 
were produced by incubation with streptavidin-allophycocyanin (SA-APC) in a 4 to 1 
stoichiometry, and to determine if the soluble TCR could bind its cognate ligand, surface 
plasmon resonance (SPR) analysis of TCR monomer and tetramers was performed by 
flowing them over immobilized Env183/A2 complexes. While monomer binding was 
below the detection limit compared to the control, specific binding of the TCR tetramers 
for the immobilized Env183/A2 complexes was detected (Fig. 3.2C).  
 
A bead-based assay to probe pMHC binding to soluble TCR tetramers.   
We explored an additional system to characterize the binding of soluble TCR and 
used streptavidin-coated beads conjugated with biotinylated soluble pMHC molecules 
(Fig. 3.3A) to provide a homogenous target with a high ligand density (44). Refolded, 
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caged HLA-A*02:01 was UV irradiated and peptide-exchanged with either Env183-191 or 
Core18-27 (control) peptide (11, 73, 83, 85, 199), immobilized on the beads and stained 
with either TCR monomers, followed by an APC-conjugated secondary detection Ab, or 
tetramers (Fig. 3.3B, C).  In agreement with the SPR data, monomer binding was below 
the detection limit, but TCR tetramer staining of the Env183/A2-coupled beads was 
increased by two orders of magnitude (Fig. 3.3C) compared to beads coated with HLA-
A*02:01 presenting the Core18-27 peptide. This demonstrated that the bead assay 
provides a sensitive system for examining the specificity of soluble TCRs. 
Consequently, different epitopes derived from the hepatitis B virus envelope, 
core and polymerase proteins, including two natural variants of the Env183-191 epitope 
(Fig. 3.4A) were peptide-exchanged into HLA-A*02:01 complexes and conjugated to the 
streptavidin-coated beads. The levels of beta-2-microglobulin (β2m), indicative of MHC 
stability, showed that the number of pMHC molecules present was approximately equal 
for all pMHC products (Fig 3.4B). The TCR tetramer bound specifically both Env183-191 
peptide variants derived from two viral genotypes but not to the other HBV epitopes 
restricted by HLA*02:01 (Fig. 3.4C). The Env183-191 epitope variants are found in either 
genotype A/C/D or genotype B viral strains and the TCR thus provides pan-specific 
recognition. This promiscuity is consistent with activation data of transduced T cells 
expressing the same α and β TCR genes (172).  
 
TCR tetramers and the analogous TCR-like mAb have distinct fine-specificities. 
It has been reported that a TCR-like monoclonal antibody (mAb) that recognizes 
the composite surface of HLA-A*02:01 presenting the Env183-191 epitope (Env183/A2 
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mAb) was capable of binding only genotype A/C/D variants of the peptide epitope and 
not the genotype B variant (172). The difference between these two peptides lies in a 
single conserved amino acid at position 187 (Lys for genotype B and Arg for genotype 
A/C/D, Fig. 3.4A). Modeling studies revealed that the arginine side chain points away 
from HLA-A*02:01, and is solvent exposed, making it available for TCR interaction (Fig. 
3.5A). To experimentally determine the fine-specificity, individual alanine substitutions at 
every position of the Env183-191 peptide were generated and loaded into caged HLA-
A*02:01 (Fig. 3.5B), which were then conjugated to beads and probed with either the 
TCR tetramers or Env183/A2 mAb. The levels of β2m were probed to ensure that the 
number of pMHC molecules on the surface was approximately equal for all pMHC 
products. Alanine substitution at position 187 had the largest impact on Env183/A2 mAb 
binding among all the alanine variants (Fig. 3.5C). While the TCR tetramer was able to 
tolerate the conservative amino acid variation between lysine and arginine (Fig. 3.4C), 
alanine substitutions had substantially reduced TCR tetramer binding (Fig. 3.5D). TCR 
tetramer binding appeared to be affected by alanine substitutions at all positions except 
the C-terminus. This observation agrees with T-cell activation data with transduced T 
cells expressing the same αβ TCR (172). The differences in binding to the presented 
peptide variants imply that although the two molecules bind the same pMHC ligand, 
they are likely to have different pMHC docking positions and/or different chemistries of 
interaction. 
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Detection limit of the bead-based assay 
 To determine the sensitivity of our assay, we titrated the soluble TCR tetramer, 
the mAb, and the amount of Env183/A2 complexes on beads. We multiplexed the 
system by employing a series of streptavidin-coated beads with varying fluorescent 
intensities. To examine the optimal concentration of TCR or mAb required for binding, 
the collection of beads were individually coated with saturating amounts of the 
Env183/A2 complexes. A titration of TCR tetramer demonstrated that TCR tetramers 
were able to bind their cognate pMHC at concentrations as low as 10 ng/mL (0.04nM) 
(Fig. 3.6A). The same collection of Env183/A2 strepavidin-coated beads was stained 
with the Env183/A2 mAb (Fig. 3.6B). Comparison of these titrations showed that at the 
same protein concentration both TCR tetramer and Env183/A2 mAb had similar avidity 
for the Env183/A2 products (Fig. 3.6C).  
Subsequently, the influence of pMHC density on binding was examined with a 
fixed concentration of soluble TCR tetramer or Env183/A2 mAb. The bead populations 
were loaded with varying amounts of Env183/A2, providing an array of beads 
presenting pMHC at different densities. Staining with anti-β2m verified the decreasing 
amounts of pMHC on the surface (Fig. 3.7C), and allowed us to quantify the number of 
pMHC per bead (Table 3.1). This revealed that, at saturation, the beads displayed 
approximately 80,000 accessible pMHC. Staining these beads with the TCR tetramer 
(Fig. 3.7A) revealed that high densities of pMHC were required for adequate detection, 
with at least more than 3000 pMHCs on their surface (Fig. 3.7D). In contrast, staining 
with Env183/A2 mAb could be achieved at 10-fold lower pMHC density (Fig. 3.7B,D). 
This increased sensitivity of the mAb we ascribe to a higher intrinsic binding affinity.  
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TCR tetramers bind cells only with high density of Env183-191/HLA-A*02:01 complexes 
Given that the tetramer of the Env183/A2-specific TCR could bind immobilized 
pMHC, we next determined if it stained T2 cells (HLA-A*02:01+, TAP deficient) pulsed 
with Env183-191 peptide. As IFN-γ treatment is known to upregulate the number of MHC 
molecules on the cell surface (26), experiments were also performed with T2 cells 
incubated with IFN-γ followed by pulsing with peptide. Monomeric TCRs did not stain 
peptide-pulsed T2 cells (Figure 3.8A) whereas TCR tetramer yielded a moderate but 
distinct increase in fluorescence specific for the Env183/A2 complex at the highest 
peptide concentration tested (Fig. 3.8B). IFN-γ treated cells displayed an increase in 
staining with the TCR tetramer at both 1 and 10 µM Env183-191 peptide (Fig. 3.8B). In 
contrast, the Env183/A2 mAb yielded a significantly greater shift in fluorescence, which 
was further increased upon IFN-γ treatment (Fig. 3.8C). The reduced staining by the 
TCR tetramer thus suggests that only a fraction of the Env183/A2 complexes on the T2 
cells are capable of retaining bound TCR tetramer after washing, reflecting the low 
affinity of the TCR (189). 
Furthermore, we compared the ability of the TCR tetramer and the Env183/A2 
mAb to recognize Env183/A2 complexes produced endogenously by HBV-infected 
cells. We utilized an EBV-immortalized B cell line (EBO-PreS1) transfected with the 
open-reading frame for the PreS1 fragment of the HBV genome (88), which expresses 
only the envelope proteins together with the Env183-191 epitope. In addition, HepG2.2.15 
cells were used, that derive from a stably transfected HLA-A*02:01+ hepatoma cell line 
bearing the complete HBV genome, expressing all viral RNAs and proteins (180). Both 
cell lines were treated with IFN-γ before staining. As the EBO-PreS1 and HepG2.2.15 
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cell lines are both TAP+, they present self-peptides in addition to HBV epitopes and the 
steady state number of Env183/A2 ligands for the Env183/A2 antibody and the TCR 
tetramer should be considerably lower than peptide-pulsed cells (Fig. 3.9). Therefore, at 
best, minimal staining was observed with TCR tetramers, yet the Env183/A2 mAb 
stained both cell lines.  
The beads with immobilized Env183/A2 complexes at various densities (Fig. 
3.7D) along with the pulsed T2 cells results suggest that although the TCR tetramers 
bound specifically, the density of the HLA complexes critically influences their binding. 
Estimates of the density of Env183/A2 on the beads, with a surface area of ~25µm2, are 
~3200/µm2 at their highest concentration. Assuming that an APC expresses 5-10 x 104 
class I MHCs on average (227) which can be pulsed to saturation with Env183-191 
peptide, a density of 800/µm2 can be achieved; which is sufficient only for detection by 
TCR-like mAb. 
Discussion 
 T cell activation is preceded by several molecular interactions; the binding of the 
peptide to an MHC product, and the binding of a TCR to this pMHC complex.  In the 
case of CD8+ T cells, activation is also critically dependent on the binding of the CD8 
co-receptor to the non-polymorphic regions of the class I MHC product. There has been 
considerable interest in using soluble extracellular domains of TCRs to probe T cell 
specificity and pMHC affinity independently from the CD8 binding synergism (43, 50, 
71).  Furthermore, soluble TCRs could in principle serve as reagents to probe surface 
expression of specific pMHC combinations on cells; particularly in cases where T cell 
activity assays are challenging (e.g. in immunohistological studies). In this study, the 
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binding and specificity of a hepatitis B virus-specific TCR was examined, and compared 
to a mAb recognizing the same Env183-191/HLA-A*02:01 antigen.  
We developed a system to sensitively discriminate the low affinity interactions 
between the pMHC and the targeting molecules. The assay employs streptavidin-
coated beads to immobilize pMHC molecules at high density, similar to what can be 
achieved with an SPR chip-based approach. When probed with multivalent TCRs or 
TCR-like mAbs, the bead populations allow rapid determination of peptide fine-
specificity by flow cytometry analysis. The bead-assay proved superior to using peptide-
pulsed APCs, which was attributed to the high surface density of the antigen (vide infra). 
Furthermore, the polymer beads gave good control over the pMHC surface distribution, 
which was easily quantified, and allowed analysis of the specific interaction in the 
absence of adhesion molecules, co-receptors and pMHC products presenting 
alternative peptides, all of which are abundantly present on APCs. 
The bead-based assay revealed that the HBV-specific TCR was properly 
assembled to recognize its cognate Env183/A2 antigen. Although the enhanced affinity 
of the TCR-like mAb holds promise for its application as sensitive probe or as targeting 
therapeutic, it differed from the corresponding TCR in its fine-specificity for the 
Env183/A2 antigen, most notably at the central 187 residue; a position where viral 
sequence variation is known to occur. The molecular model that we generated for the 
Env183-191/HLA-A*02:01 complex prominently featured a protruding basic amino acid 
residue (i.e. Arg187 for HBV genotypes A/C/D, or Lys187 for HBV genotype B) from the 
binding pocket, and highlighted it as a important candidate residue for interaction with 
the TCR or the mAb. As the naturally occurring R187K mutation between HBV 
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genotypes A/C/D and genotype B already eliminated binding by the Env183/A2 mAb, 
the R187A substitution was equally disruptive to binding, as would be predicted (172). 
The TCR tetramers, on the other hand, bound both the R187 and K187 epitope 
variants, although the more profound R187A mutation did interfere with its specific 
recognition.  
The half-life of TCR:pMHC interactions ranges in seconds, whereas 
oligomerization can extend that by several hundred-fold, thus enabling TCR tetramers 
to stably bind pMHCs long enough to employ them experimentally as surface staining 
reagents (115). The avidity gained through tetramerization of our Env183/A2-specific 
allowed the TCR tetramers to bind beads as well as the Env183/A2 mAb when 
saturated with the correct pMHC. The sensitivity of staining was clearly dependent on 
the degree of packing of pMHC on the beads, presumably because at higher density the 
TCR tetramer can bind clusters of pMHC simultaneously. In our hands, the TCR 
tetramer showed appreciable staining when loading of the individual beads, with a 
diameter of ~2.7µm, reached above 3,500 pMHC molecules. For a typical hepatocyte, 
with a diameter of ~20-40µm (58), the number of surface pMHCs must be 50-fold higher 
to attain similar densities. Therefore, to achieve the same level of staining as observed 
in our bead assay, over 175,000 Env183/A2 complexes would have to be presented. 
Hepatocytes, however, are poor antigen presenting cells with low expression levels of 
class I MHCs (79) and their capacity for antigen presentation is inefficient (227), making 
these specific viral pMHC products rare in a clinical setting. A caveat of this estimate for 
the lower limits of detection, is that it assumes random distribution over membrane, 
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whereas pMHC molecules could conceivably cluster (70, 100, 131). It therefore remains 
to be established if such clustering might allow binding by multivalent TCR constructs. 
Collectively, we demonstrated the utility of the bead-based flowcytometry assay 
in conjunction with the peptide-exchange strategy for pMHC (11, 44, 73, 83, 85, 167, 
199) to rapidly characterize the antigen-specificity and cross-reactivity of soluble TCRs 
and TCR-like mAbs, which is of significance especially when the two have demonstrably 
different docking orientations to their cognate pMHC (23, 134). Our results also 
underscore that antigen distribution is an essential parameter to be considered during 
the development and design of novel diagnostic and immunotherapeutic intervention 
strategies. 
Figure 3.1. FPLC purification profiles of in vitro refolded soluble TCR. In 
vitro refolded TCR was purified by size exclusion chromatography (A) followed 
by anion exchange chromatography (B). Fractions collected, indicated in red 
boxes, from size exclusion chromatography were pooled and further purified by 
anion exchange chromatography. Two gradients were used for elution in the 
anion exchange purification step. A short 0-15% gradient was followed by a 
long 15-25% gradient of elution buffer (20mM Tris, pH 8.0 with 1M NaCl), 
replacing the binding buffer (20mM Tris, pH 8.0) 
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Figure 3.2. Protein analysis of purified soluble full length TCR. (A) Analysis 
of two distinct peaks obtained after ion exchange purification (Fig 1B) of 
refolded TCR showed that P1 contained predominantly monomers while P2 
contained dimers. (B) Gel shift analysis of the refolded TCR product. The 
streptavidin Western blot showed biotinylation in Beta chain IB and refolded 
TCR. (-S, without streptavidin, +S, with excess streptavidin) and that >90% of 
the dimers were biotinylated. (C) Surface plasmon resonance analysis of 
refolded TCR tetramers demonstrated specificity for immobilized Env183/A2. 
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Figure 3.3. Peptide MHC complex coated beads as an artificial antigen 
presenting cell. (A) Schematic of the fluorescent bead assay. Streptavidin-
coated beads were loaded with biotinylated pMHC monomer thus providing a 
homogenous binding surface for the Env183/A2 mAb or TCR tetramers (B) 
Beads were stained with 10µg/mL of monomeric TCRs or (C) 1µg/mL APC-
conjugated TCR tetramers. Monomeric binding was probed using an anti-TCR 
antibody. Beads presenting Core18-27 HLA-A*02:01 were used as a control.  
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Figure 3.4. Soluble TCR binds specifically to Env183-191 pMHC and 
recognizes both natural variants Genotypes A/C/D and Genotype B. (A) 
Beads were loaded with HLA-A*02:01 presenting 6 different peptides and 
stained with a mouse anti-β2m followed by detection with an APC-conjugated 
goat anti-mouse antibody. (B) Staining shows equal levels of pMHC on beads. 
(C) The beads were furthermore stained with 1µg/mL APC-conjugated TCR 
tetramers, showing that they only bound Genotype A/C/D and Genotype B 
variants of Env183-191 peptides presented by HLA-A*02:01 
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Figure 3.5. Comparison of fine specificity of Env183/A2 antibody and 
soluble TCR tetramers. (A) The Env183-191 peptide modeled into the Tax/HLA-
A2 crystal structure, inset: lateral view of the peptide in HLA-A*02:01. The 
Arg187 side chain protrudes from the binding pocket, potentially interacting with 
the TCR or antibody. (B) Nine different Env183-191 peptides with single position 
alanine substitutions were used to probe the fine specificity. (C and D) The 
alanine variant pMHCs were loaded onto beads and stained with Env183/A2 
mAb or TCR tetramer (1µg/mL). !
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Figure 3.6. Functional avidity of the Env183/A2 antibody and soluble TCR 
tetramers. A range of beads of different fluorescent intensities were saturated 
with pMHC and stained with titrating amounts of (A) TCR tetramer or (B) 
Env183/A2 mAb. (C) The titration profiles of the TCR tetramer and the Env183/
A2 mAb showed that both reagents had similar avidity for the pMHC.  
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Figure 3.7. Peptide MHC sensitivity comparison of Env183/A2 antibody 
and soluble TCR tetramer. An array of beads presenting pMHCs at different 
densities was generated, as confirmed and quantified by anti-β2m staining. 
These beads were incubated with 1µg/mL of (A) TCR tetramer or (B) Env183/
A2 mAb. (C) Levels of pMHC presented on the surface of the beads used in (A) 
and (B) was determined by staining with a mouse anti-b2m antibody. (D) 
Graphical representation of staining intensity for the different bead populations. 
Whereas the antibody bound beads presenting 200 complexes, the TCR 
tetramer required at least 3500 complexes for similar staining. 
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Figure 3.8. Recognition of exogenously pulsed pMHC presented on the 
surface of cells.  (A) TCR monomers were used at 1µg/mL and 5µg/mL to 
stain T2 cells pulsed with 10µM Env183-191 peptides. Binding of monomers was 
probed using an anti-αβTCR antibody. No significant staining of TCR 
monomers was seen. The E183/A2 monoclonal antibody was used as a 
positive control. (A) Untreated (-) and T2 cells treated (+) with IFN-γ were 
pulsed with 1 or 10µM of Env183-191 or 10µM of Core18-27 peptide control and 
stained with 1µg/mL TCR tetramer. (B) Identically treated T2 cells stained with 
1µg/mL Env183/A2 mAb demonstrates that both treatment with IFN-γ and 
pulsing with higher peptide concentrations results in a higher surface 
expression of Env183/A2 complexes. .  
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Figure 3.9. Recognition of endogenously presented pMHC complexes. 
HepG2.2.15 and EBO-PreS1 cells, transfected with the full and PreS1 
fragment of the HBV genome, respectively, endogenously process and 
present Env183/A2 pMHC complexes on their cell surface. The TCR-like mAb 
(dashed) shows improved detection compared to the TCR-tetramers (solid). 
Peptide pulsed HepG2.2.15 and EBO-PreS1 further increased surface levels 
of Env183/A2 (filled histograms). TCR tetramers did not give significant 
staining with unpulsed or pulsed cells. 
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Dilution 
Factor 
pMHC 
added 
per bead 
Thereotical 
no. of beads 
conjugated 
per bead 
MFI of 
β2m 
staining 
 
No. of 
Complexes 
by Qifi™ 
Kit 
No dilution 1.81 x 107 2.268 x 106  18694 78789 
1 in 4 4.52 x 106 2.268 x 106  18522 78021 
1 in 16 1.13 x 106 1.13 x 106 9153 36943 
1 in 64 2.82 x 105 2.82 x 105 5315 20757 
1 in 256 7.05 x 104 7.05 x 104 996 3514 
1 in 1024 1.76 x 104 1.76 x 104 246 797 
1 in 4096 4406 4406 133 415 
1 in 16384 1101 1101 63.5 190 
1 in 65536 275 275 64 191 
1 in 262144 69 69 57.8 172 
Table 3.1. Quantification of pMHCs presented on streptavidin-coated 
beads. The QIFI™ quantification kit contains 5 beads conjugated with known 
number of mouse IgG. IgG. The beads were stained with an APC-conjugated 
goat anti-mouse and the mean fluorescent intensity (MFI) of each bead 
population was recorded. A linear regression was determined between the 
log(MFI) and log(no. of IgG) and the parameters were used for later 
calculations of pMHC numbers on the streptavidin beads. Beads stained with a 
mouse anti-β2m antibody (Figure 3.10C) and subsequently with the same APC-
conjugated goat anti-mouse antibody used to stain the QIFI™  beads and the 
number of pMHC complexes were calculated based on the mean fluorescence 
intensity of each anti-b2m staining. 
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CHAPTER FOUR 
 
DEVELOPMENT OF PEPTIDE-MHC-COATED BEADS FOR DETECTION OF T CELL 
RECEPTORS IN A YEAST DISPLAY SYSTEM 
 
Introduction 
 The T cell receptor (TCRs) binds to an antigenic peptide presented on the cell 
surface by a protein encoded by the major histocompatibility complex (MHC) with low 
affinities (KD values between 1-100µM) (112). This recognition process is also 
challenging because the number of specific peptide-MHC complexes is usually low, as 
few as about 10 per target cell (226). These factors limit the application of soluble 
versions of the TCR as a peptide-MHC complex (pMHC) targeting tool. However, the 
ability to engineer proteins for improved binding has developed over the past years. 
Accordingly, various systems including phage display, yeast display, mammalian cell 
display, insect cell display and ribosome display have been used as a platform for the 
expression and directed evolution of mutant proteins (25, 29, 41, 118, 128). Each 
system has its advantages and disadvantages. For example, while mammalian cells 
might be preferred for the expression and display of membrane proteins such as the 
TCR, the library diversity is limited by the efficiency of retroviral transduction and the 
number of cells that can be handled. Yeast and phage display systems allow libraries 
with diversity orders of magnitudes larger than mammalian cell systems, but expression 
and display of stable proteins may be hampered by the lack of the required post-
translational modifications or other cellular machinery. Nevertheless, several groups 
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have reported success using the yeast, phage and mammalian display systems in the 
engineering of TCRs (41, 95, 118). 
 The antigen binding site of a TCR consists of hypervariable loops in the α and β 
variable domains, known as the complementarity determining regions (CDRs). Each 
variable domain contributes three CDRs with a total of six CDRs determining the 
specificity and affinity of the TCR. Importantly, CDR3 loops of each variable domain are 
encoded by the junctions (VJ or VDJ) at RAG recombination site. Thus, these loops 
show the most extensive diversity in sequence and length. As the TCR docks diagonally 
over the pMHC ligand, both CDR3 loops are positioned primarily over the peptide while 
the CDR 1 and 2 loops are focused primarily on the binding of the helices of the MHC 
molecule (76, 112, 170). Hence, diversity of CDR3 loops in TCRs play a major role in 
conferring peptide specificity; accordingly, to retain peptide specificity, the CDR3 loops 
are an attractive target for mutagenesis and affinity maturation.  
 The mouse 2C TCR was the first TCR to be engineered for higher affinity, using 
the yeast display system. The 2C TCR recognizes a peptide called QL9 peptide 
restricted by the allogeneic MHC class I molecule Ld and the foreign peptide called SIY 
presented by the syngeneic MHC class I molecule Kb. The 2C TCR has been expressed 
in a single chain, Vβ-linker-Vα, form (scTCR) and higher affinity mutants have been 
isolated by mutating amino acid residues in the CDR3α and CDR3β regions (47, 95). 
Similarly, the human A6 TCR specific for the human T-lymphotropic virus (HTLV) Tax 
peptide restricted by the human MHC class I molecule HLA-A2 and the 1G4 TCR 
specific for tumor-associated peptide antigen, NY-ESO-1 also restricted by HLA-A2 had 
been engineered with mutations in the CDR3β and CDR3α regions (118). In addition, it 
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has also been shown that affinity can be improved with mutations in the CDR1 and 
CDR2 regions (47, 61, 118). Thus, all six CDRs are potential candidates for 
consideration when designing mutant libraries.  
 The number of residues to be mutated, and hence the overall theoretical 
diversity, is limited by the size of the library achievable by the display system. For 
example, a library containing 5 randomized amino acid positions would theoretically 
contain 3.2x106 possible amino acid sequences. Employing the NNS codon degeneracy 
(where N: adenine, cytosine, guanine or thymine; S: guanine or thymine), covering all 
20 amino acids with 32 possible codons, the library would theoretically contain 3.3x107 
possible nucleotide sequences. To cover all possible sequence space also requires 
oversampling due to probability issues and PCR or codon synthesis biases. There are 
also limitations imposed by transformation efficiency (107-108 transformants/µg plasmid 
in yeast display (14, 165)) during the generation of the library, the sensitivity and 
efficiency of analytical techniques used for the screening of the library (e.g. 
fluorescence-activated cell sorting) and other practical issues such as time and cost. 
Hence, library design and screening approaches will influence the success of 
engineering an affinity-matured protein. 
 In the yeast display system, TCRs have been screened with fluorescent-labelled, 
soluble forms of pMHC ligands, often in the form of immunoglobulin-linked dimers or 
streptavidin conjugated-tetramers, followed by fluorescence-activated cell sorting 
(FACS). Yeast displayed libraries are typically subjected to repeated rounds of cell 
sorting with successive reduction in ligand concentrations. This increases the stringency 
of selection during each sort, creating the selective pressure required to isolate mutated 
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cloned with the highest affinity. Ideally, a mutant library covering all six CDRs would 
provide the diversity required to isolate the best solutions for affinity-matured variants. 
However, this would involve the construction of library sizes that are not achievable. 
The availability of structure-activity data can enable a semi-rational design of libraries in 
which key residues are selected for mutagenesis, thereby reducing the required library 
size. Unfortunately, structural studies of TCRs have been less successful than 
antibodies, largely due to the difficulty in producing soluble TCRs (169). 
 This chapter presents studies based on the premise that better selections 
strategies would be capable of isolating higher affinity TCR mutants, even if the library 
sizes, and thus sequence space, are not optimal. Specifically, it examines whether the 
multivalent bead approach used in Chapter 3 would facilitate the isolation of higher 
affinity TCR mutants from yeast display libraries.  
 It has now been over 15 years since the first use of multimeric pMHC molecules 
enabled the detection and study of antigen specific T cells (6, 54). The avidity provided 
by multimeric pMHC prolonged the fast dissociation rates associated with the weak 
TCR:pMHC interaction, allowing for detection by flow cytometry. Similarly, dimeric and 
tetrameric pMHC had also been employed in the screening of yeast displayed TCR 
libraries (47, 94, 95). In this chapter, I present a strategy to screen yeast displayed TCR 
libraries with sensitivity that is even greater than dimeric and tetrameric pMHC, by 
employing the use of streptavidin-coated beads. Biotinylated pMHCs were immobilized 
on the surface of the streptavidin-coated beads at high densities, to provide a detection 
reagent with higher sensitivity than achievable with dimers or tetramers. To 
quantitatively examine the system, yeast displaying the single-chain 2C TCR with wild 
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type affinity and the higher affinity variants called Y48A and m33 that bind the SIY/Kb 
pMHC with KD values of 30µM, 3µM and 30nM, respectively, were used.  Using these 
model TCRs, I showed that the multivalent pMHC beads have greater sensitivity than 
conventional dimeric and tetrameric reagents. To apply the approach to a TCR library of 
mutants, I used the pMHCs beads to screen a de novo library, isolating both high and 
intermediate affinity TCR variants. Only the high affinity variants were isolated using the 
less sensitive reagents such as pMHC tetramers and dimers. In summary, I present a 
new strategy in library screening whereby the use of multivalent pMHC beads allowed 
the identification of both intermediate and higher affinity mutants in a TCR library. The 
approach will be useful in the case of protein engineering in which libraries lack the 
highest affinity solutions due to constraints in the design or construction of the library. 
Such intermediate affinity solutions can then serve as the leads for additional library 
construction and affinity improvements.    
 
Materials and Methods 
Yeast display of single-chain and full-length T cell receptors 
 The single-chain form of the wild type 2C TCR, 2CT7 was engineered previously 
for yeast surface expression (108) while the high affinity mutant m33 was generated by 
directed evolution in a yeast display system (94). The Y48A mutant is a single-residue 
variant of the m33 mutant in the CDR2β region (Y48βA) (43). The single-chain form of 
the Tax-HLA-A*02:01 (Tax/A2) specific A6 TCR (X15) was previously generated by 
random mutagenesis in a yeast display system (2). All scTCRs were cloned in the yeast 
display vector pCT302, and expressed on the surface of yeast as a fusion to the cell 
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wall protein Aga2. EBY100 yeast cells were transformed with the scTCR containing 
yeast display plasmids and cultured in Trp- media at 30°C for selection. Expression of 
the TCR genes was induced by transfer to galactose containing media and cultured at 
20°C.  
Full-length β-chain (VβCβ) of the HBV Core18/HLA-A*02:01 specific TCR was 
cloned into the yeast display, Aga2 plasmid p315 while the α-chain was cloned into the 
pCT302-NAGA yeast secretion plasmid. The p315 plasmid contains a leucine 
biosynthetic selectable marker that allows transformants to be cultured in Leu- media 
while the pCT302-NAGA plasmid contains a tryptophan biosynthetic selectable marker 
that allows transformants to be cultured in Trp- media. Double transformants were 
selected in Leu--Trp- selection media. Induction of expression of the TCR genes from 
both plasmids was done in galactose containing media at 20°C. 
 
In vitro refold and biotinylation of pMHC complexes 
 Heavy chain and β2-microglobulin (β2m) subunits of the mouse Kb and human 
HLA-A2 class I MHC molecules were expressed individually in BL21 E. coli cells. 
Inclusion bodies were harvested after induction of BL21 cultures and purified before 
refolding in vitro with the appropriate peptides. Refolding was done in refold buffer 
(100mM Tris pH8.0, 400mM L-Arg HCl, 2mM EDTA) supplemented with 0.5mM 
oxidised glutathione and 5mM reduced glutathione in the presence of excess peptides 
at 4°C. Heavy chain and β2m inclusion bodies were introduced in three separate doses 
8-12 hours apart and allowed to refold before purification by size exclusion 
chromatography. In vitro biotinylation was done enzymatically using biotin ligase 
 92 
according to manufacturer’s instructions (Avidity, LLC) and biotinylation of the refolded 
pMHCs was verified by gel-shift with streptavidin by SDS-PAGE (Figure 4.1A). 
 
Production of and yeast cell staining with pMHC beads  
 Blue (SVBP-03-10) and yellow (SVFP-0552-5) fluorescent streptavidin-coated 
beads (Spherotech Inc) beads were first pre-incubated with 200µL of wash buffer (2% 
BSA in PBS) for 30 minutes with shaking and then incubated in with pMHC in wash 
buffer for 30 minutes with shaking. Binding capacity of the beads was calculated based 
on the manufacturer’s specifications. pMHC-loaded beads were washed with blocking 
buffer and suspended in wash buffer to the required concentration. Immobilization of 
pMHC on the surface of beads was probed with an anti-β2m antibody and analysed by 
flow cytometry (Figure 4.1B). Yeast cells were stained with pMHC beads at room 
temperature for 30 minutes with shaking. Stained cells were washed twice with wash 
buffer before flow cytometric analysis.  
 
Fluorescence-activated cell sorting of de novo library 
 The de novo scTCR library was designed and provided by Sheena Smith. The 
library, which contained degeneracy at 5 selected amino acids, was synthesized by 
Genescript, and cloned into the pCT302 yeast display vector. Yeast cells transformed 
with the yeast library were grown in Trp- media for selection and induced for TCR 
expression before sorting.  
Streptavidin beads were supplied in storage buffer containing 0.02% sodium 
azide (w/v) to prevent microbial contamination. To assess toxicity and sterility of the 
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beads, they were first washed thoroughly in excess sterile washing buffer and added to 
growing yeast culture. No contamination or toxicity was observed.  
In general, 107 cells were stained with 10µg/mL (with respect to pMHC) of pMHC-
coated blue fluorescent beads for 30 mins at room temperature. After incubation, the 
cells were washed and suspended in washing buffer before sorting. The top 1% (0.5% 
for the final 2 sorts) of cells exhibiting specific binding by detection of blue fluorescence 
in the APC channel were isolated and collected using a BD FACSAria fluorescence-
activated cell sorter. Collected cells were expanded in Trp- media before subsequent 
induction and sorting. Cells collected after 4 sorts were expanded in culture and plated 
on Trp- media for the isolation of single clones that were analyzed for binding. The 
pCT302 yeast display vectors of individual clones were recovered using the Zymoprep 
kit (Zymo Research) according to manufacturer’s instructions and amplified by PCR 
before submission for DNA sequencing. 
 
Results 
Production of pMHC-coated beads 
 The murine TCR 2C binds the peptide SIY (SIYRYYGL) in complex with the 
class I molecule Kb (SIY/Kb), while the human A6 TCR recognizes the human T-cell 
leukemia virus (HTLV) Tax11-19 peptide in complex with the class I molecule HLA-
A*02:01 (Tax/A2) (201, 204). To evaluate the use of the streptavidin-coasted beads as 
a scaffold for pMHC presentation, recombinant soluble SIY/Kb and Tax/A2 pMHC were 
refolded in vitro, purified and biotinylated. Biotinylation of the refolded products were 
probed by a streptavidin gel shift assay using SDS-PAGE. Figure 4.1A shows that at 
 94 
least 50% of the refolded pMHCs were biotinylated. The biotinylated pMHC were then 
used to generate the multivalent pMHC coated-beads. The binding capacities of the 
streptavidin-coated beads were calculated based on technical specifications provided 
by the manufacturers. The concentration of pMHCs used for immobilization was then 
based on achieving 5-fold excess over the binding capacity of the beads, in order to 
ensure saturation. The densities of pMHC on the surface of the beads were probed 
using an antibody specific for the β2-microglobulin (β2m) subunit of the pMHC 
complexes. Figure 4.1C shows that when a titration of pMHC concentrations is used 
during incubation, ranging from 5:1 to 0.0005:1 pMHC to streptavidin binding site ratio, 
beads conjugated with various densities of pMHC can be made and that 5-fold excess 
of pMHC was sufficient to achieve saturation.   
 
pMHC beads have higher sensitivity than dimeric or tetrameric pMHCs 
 The current “gold standard” for analyzing T cells or isolating yeast-displayed TCR 
mutants are multimeric pepMHC ligands produced with Ig-fusions or streptavidin. To 
examine the use of multimeric beads, I used the 2C yeast display system. Wild-type 2C 
TCR binds to SIY/Kb pMHC with a KD value of 30µM, while the high-affinity m33 mutant 
binds 1000-fold better with a KD value of 30nM. The single-amino acid mutant of m33, 
called Y48A, binds with an intermediate affinity of 3µM (43, 78). Collectively, these 
provided a useful system with a wide range of affinities to explore the limits of binding 
by the various multimeric forms of SIY/Kb.   
Yeast cells expressing the single-chain stabilized form of the wild type 2C 
receptor (called 2CT7), m33 and Y48A were induced and cells were stained with 
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dimeric SIY/Kb (DimerX, an immunoglobulin fusion of Kb), SIY/Kb tetramers of 
streptavidin, and SIY/Kb-coated beads. The concentration used of each reagent was 
fixed with respect to SIY/Kb molecules at 10µg/mL (200nM). Dimeric and tetrameric 
forms of the SIY/Kb pMHC were able to stain only the highest affinity mutant m33, but 
not 2CT7 of wild type affinity or the Y48A mutant with intermediate affinity (Figure 4.2A 
and B)(Note: negative populations, as seen in the staining of m33, are invariably 
observed in all yeast-displayed systems as a result of cells that have lost plasmid during 
induction; this population serves as an internal negative control). The ability to stain 
m33 but not 2C or Y48A with tetramers had also been shown previously (43). In striking 
contrast, the SIY/Kb-coated beads were able to bind both the high and intermediate 
affinity receptors, and also had modest staining of the low-affinity wild type TCR, 2CT7 
(Figure 4.2C), as compared to the background staining with the control OVA/Kb-coated 
beads (Figure 4.2D). SIY/Kb-coated beads staining of the highest affinity TCR m33 also 
exhibited fluorescence intensity that was almost ten-times that of the dimer or tetramers, 
providing a system with further enhanced sensitivity. 
 The sensitivity of the pMHC-coated beads was further tested with the use of 
variants of the SIY peptide (SIYRYYGL) with known effects on 2C and m33 binding. 
The structure of 2C-SIY/Kb shows that both the side chains of the Arg residue at 
position 4 (R4) and the Tyr residue at position 6 (Y6) point toward the 2C TCR (Figure 
4.3A). T cell-activation assays were done with 2C TCR transfectants, showing that 
levels of IL-2 release were affected when alanine substitutions were made at these 
positions of the SIY peptide, even when antigen-presenting cells were pulsed with high 
concentrations of peptides (100µM) (31). In addition, a TCR mutant (m67) similar to 
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m33 showed about 100-fold lower affinities for these two SIY variants, bound to Kb (31).  
To look at the effect of these substitutions on TCR binding, recombinant SIY(R4A)/Kb 
and SIY(Y6A)/Kb were refolded in vitro, immobilized on streptavidin beads (as verified 
with anti-β2m staining, Figure 4.2B), and used to stain yeast cells displaying the 2CT7, 
Y48A and m33 TCRs. Both peptide variants significantly reduced binding to Y48A and 
m33 TCRs. The R4A variant had a more profound effect compared to Y6A as binding 
was reduced to levels equivalent to that observed with the beads conjugated with the 
non-cognate OVA/Kb pMHC control (Figure 4.2D). The effects of these SIY peptide 
variants on binding to the wild type 2C receptor were previously untested due to 
limitations of detection when using tetrameric pMHCs or soluble 2CT7 scTCRs (31, 43). 
However, with pMHC-coated beads, the Y6A substitution is observed to result in a 
modest reduction in binding to the wild-type 2C receptor as compared to its effect on 
binding to the higher affinity mutants (Figure 4D), while the R4A substitution had a 
larger effect on binding to the TCR (Figure 4E). These results also suggest that the 
sensitivity of the pMHC beads is over 100-fold improved compared to dimers and 
tetramers, with a sensitivity of at least a KD value of 30µM. 
 
Sensitivity of pMHC staining varies with beads concentration and pMHC density. 
 During the screening of a yeast-displayed TCR library, stringency of selection 
can be increased after each rounds of sorting by decreasing the concentration of pMHC 
used during staining. With the pMHC beads, the concentration of pMHC can be varied 
in two different ways. First, assuming each bead is saturated according to the calculated 
binding capacity, the concentration of pMHC can be approximated by the number of 
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beads used for staining. A titration of SIY/Kb beads, representing pMHC concentrations 
of 1ng/mL to 10µg/mL, was thus used to stain yeast cells expressing 2CT7, Y48A and 
m33 TCRs on their surface. Figure 4.4 shows that the binding of the three TCRs to the 
SIY/Kb beads gradually decreases when lower concentrations of SIY/Kb, were used. 
Specific binding of low affinity wild-type 2CT7 TCR to SIY/Kb beads as compared to the 
control OVA/Kb beads was detectable even when the pMHC concentration was as low 
as 100ng/mL (2nM). 
 Another approach to varying the pMHC density on beads is to titrate the 
concentration of pMHC used during bead preparation, at a fixed number of beads. As 
shown in Figure 4.1C, saturation of beads was observed when a 5-fold excess of 
pMHC, above the number of biotin binding sites, was used. To generate beads 
presenting different densities, the amount of pMHC used was titrated in 10-fold 
dilutions. Excess streptavidin binding sites were blocked with free biotin, and the density 
of conjugation was probed by staining with an anti-β2m antibody Figure 4.1C. Equal 
amount of the beads were then used to stain yeast cells displaying the 2CT7, Y48A and 
m33 TCRs. These results showed that only the two highest concentrations of SIY/Kb 
used, when the beads are fully saturated (Figure 4.1C), were capable of detecting the 
2C and Y48A TCRs. Below these densities the beads presumably have insufficient 
avidity for specific binding and retention during flow cytometry. In contrast, the m33 TCR 
yields staining at ten-fold lower densities, consistent with the ability of pMHC dimers or 
tetramers to detect this TCR. In summary, the density of pMHC in beads can be tuned 
to achieve the selection of TCRs within a desired range of affinities, to affinities as low 
as 30 µM.   
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Selection of TCRs with intermediate and high affinities from a scTCR library with pMHC 
beads 
 Having demonstrated the ability of the beads to bind low affinity scTCRs 
displayed on the surface of yeast, I next tested whether the beads could be used to 
screen a scTCR library. A proprietary library based on the A6 TCR, specific for the 
HTLV Tax peptide restricted by the human MHC class I molecule HLA-A*02:01 
(Tax/A2), was designed and generated by Sheena Smith. Recombinant HLA-A*02:01 
complexes with the Tax peptide, and a control hepatitis B virus peptide Core18-27 
(C18/A2) were refolded in vitro and purified. These pMHC were prepared in sterile 
conditions and used in saturation (10µg/mL of pMHC) to coat streptavidin beads. The 
Tax/A2 and C18/A2 beads were used to stain the unsorted A6 library (Figure 4.5A). The 
top 1% of cells that stained positive were subsequently sorted and expanded in culture 
media. Three further rounds of sorting were done with the top 1% (2nd round) and 0.5% 
(3rd and 4th rounds) of binders collected and cultured. Figure 4.5B summarizes the 
binding profiles of the cells collected after each round of sorting. After 4 rounds of 
sorting, a population of yeast cells that bound to Tax/A2 beads strongly was enriched, 
whereas no such population was isolated in the sorts using the C18/A2. This suggests 
that the population enriched was specific for the cognate Tax/A2 pMHC and not due to 
non-specific binding to the bead scaffold. 
 
Isolation and characterization of Tax/A2 binding clones 
 Yeast cells collected from the 4th sort of the Tax/A2 selections were plated and 
individual clones were picked for further characterization. The clones were analyzed in 
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comparison to the single-chain, stabilized, high-affinity mutant X15 (2). Twenty 
individual clones were induced for expression, and then stained with either Tax/A2 
beads or the control C18/A2 beads, at the pMHC concentration used for sorting. For 
comparison, the clones were also stained with Tax/A2 and C18/A2 tetramers at the 
same pMHC concentrations.  
The A6 X15 TCR is the single-chain stabilized form of the A6 mutant clone 134, 
which was engineered for high-affinity (KD value of 2.5nM) previously by phage display 
(2, 118). Figure 4.6A shows the binding histograms of yeast-displayed X15, stained with 
either Tax/A2 beads or Tax/A2 tetramers. As with the m33 high-affinity TCR, both the 
beads and tetramers were capable of staining X15, although the beads yielded 
enhanced fluorescence intensity.  In comparison to X15, two different classes of clones 
were identified from enriched cells (Figure 4B): 1) Yeast-displayed TCR mutants that 
bound strongly to both Tax/A2 beads and Tax/A2 tetramers (designated as strong 
binders) and 2) Yeast-displayed TCR mutants that bound to Tax/A2 beads but bound 
poorly or not at all to Tax/A2 tetramers (designated as intermediate binders). Figure 
4.6B shows the binding profiles of 3 examples of each class of TCRs. Again, in 
comparison to the staining profiles of the three 2C TCRs (Figure 4.2), the strong binders 
are similar to the high-affinity m33 while the intermediate binders more closely resemble 
the Y48A mutant.   
 Three strong binders and three intermediate binders were further characterized 
by performing a titration with Tax/A2 beads and Tax/A2 tetramers. The titration profiles 
of the strong binders showed that they bound similarly (H4-1 and H4-11) or stronger 
(H4-3) than the high affinity X15 clone (Figure 4.7A), while they were negative for 
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staining with the control C18/A2 beads and tetramers.  The titration profiles of the 
intermediate binders showed reduced binding to both Tax/A2 beads and Tax/A2 
tetramers in comparison to clone X15 (note the y-axes for the intermediate binders 
differs from the strong binders by several fold). There was some specific binding at the 
highest concentrations of tetramers tested. In addition, sequences of the yeast display 
plasmids recovered from the strong and intermediate binders showed yielded unique 
sequences (data not shown). These findings support the idea that the pMHC bead-
based approach can yield TCR mutants that are likely to have a wider range of affinities 
than can be isolated with pMHC tetramers. The expression of soluble forms of the 
scTCRs and their analyses by surface plasmon resonance will be required to confirm 
this finding and to determine the range of affinities associated with the mutants. 
 
Screening for HBV C18/A2 specific TCRs from a full-length TCR library with pMHC 
beads 
 TCRs engineering by yeast display has been done previously with single chain 
forms of TCRs expressed as a Vβ-linker-Vα fusion protein on the surface of the yeast 
cell. However, these truncated TCRs are not stable and require additional mutagenesis 
to isolate stabilized forms of the single-chain fusion protein (2, 163). An alternative to 
expressing the Vα-linker-Vβ form is to display full-length receptors (VαCα and VβCβ), 
excluding the stalk and intracellular regions, on the surface of yeast cells. While such a 
strategy has been used in the engineering of high-affinity TCRs by phage display 
system (61, 115), it has not been used in the yeast display system. Toward this effort, 
here I cloned the genes for a TCR specific for the hepatitis B Core18-27/HLA-A*02:01 
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(C18/A2) into the yeast display system, and I attempted to use the pMHC beads 
strategy to isolate affinity-matured mutants from full-length CDR3α-libraries of the TCR.  
 Single transformants expressing yeast-displayed β-chain of the C18/A2 TCR 
were first generated by transforming EBY100 yeast cells with the p315 yeast display 
vector containing the full-length VβCβ gene (Figure 4.8A). Transformants were 
screened for expression of the β chain using an anti-human TCR Vβ8.2 monoclonal 
antibody specific for the C18/A2 TCRβ chain and the highest expressing yeast cells 
were used for a second transformation with the pCT302-NAGA secretion plasmid 
containing the VαCα gene. Due to the lack of an antibody specific for the Vα3 of the 
C18/A2 TCRα chain, a c-Myc epitope tag was added to the C-terminal end of the VαCα 
gene as a probe for expression (Figure 4.8A). To facilitate the association of the 
secreted α chain and yeast displayed β chains, a non-native disulfide bond was 
engineered in the C regions, as described previously (30). Figure 4.8B shows the level 
of display, and presumably association, of the α and β chains on the surface of double 
transformants. These cells were incubated with the C18/A2 beads but staining above 
the background was not observed. To determine if this might be due to the relatively low 
fraction of cells that expressed the α chain, the sample was sorted with anti-c-Myc 
antibody. Sorting of the pCT302-NAGA-VαCα plasmid transformed cells with the anti-c-
Myc antibody yielded a population that was enriched for expression of the c-Myc-
containing α chain. However, these cells were not positive for staining with C18/A2 
beads.  These results indicate that either the α and β chains are not properly associated 
on the yeast surface, or the affinity of this wild-type TCR is very low. 
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 To examine if a higher affinity mutant might be isolated, two libraries with 4-
codon amino acid degeneracy in the CDR3α the C18/A2 TCR were produced (Table 
4.1). PCR products containing the degeneracies were co-transformed with the 
linearized vector into yeast cells to generate the two full-length CDR3α libraries (Lα1 
and Lα2). Lα1 and Lα2 were first subjected to a round of sorting based on c-Myc 
staining to enrich for α chain expression (Figure 4.8C). These populations were 
cultured, induced, and incubated with C18/A2 beads at a pMHC concentration of 
10µg/mL. Four rounds of sorting was performed, with the top 1% of binders collected 
during the first two rounds and the top 0.5% of binders collected in the 3rd and 4th 
rounds. However, no enrichment of yeast mutants that bound to C18/A2 beads was 
observed after four sorts (Figure 4.8D). 
 Possible explanations for the failure to enrich affinity matured pMHC binders are: 
1) the level of properly associated αβ heterodimeric TCR on the surface of the yeast is 
low, even though both chains were detectable, 2) the CDR3a libraries produced did not 
contain a high-affinity “solution”. In regard to the first possibility, as shown in Chapter 3, 
the efficiency of a multivalent reagent is dependent on the density of the target since the 
benefit of multivalency is the simultaneous binding of the multiple ligands and thus 
prolonging the off-rate (54). In the full-length system, the functional heterodimeric TCR 
is formed by the yeast displayed β chain and the secreted α chain. The yeast cells 
expressing either the wild-type C18/A2 TCR (Figure 4.8B) or the CDR3α libraries 
(Figure 4.8C) expressed high levels of expression of the β chain, similar those seen in 
the scTCR system. However, the levels of α chain secreted and associated with the β 
chain on the surface of the yeast (represented by the levels of c-Myc epitope) is 
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considerably lower, and it is unclear what fraction of this may have properly associated 
Vα and Vβ domains.  Thus, the actual levels of TCRs displayed on the surface of the 
cells are likely to be lower than that seen in the scTCR system.  
The second possibility, that the four-codon CDR3α libraries did not contain a 
solution that yielded higher affinity.  It has been observed in the 2C system, that as 
many five contiguous mutations were likely necessary to isolate some of the high-affinity 
TCRs (94). In addition, it is possible that mutations in the CDR3β, or even other CDRs, 
may have generated TCR variants with higher affinity “solutions”.  These studies would 
require the generation of additional libraries to determine if they contained such high-
affinity TCR variants. 
 
Discussion 
 The ability to detect antigen-specific T cells is hindered by the low affinity of the 
TCR:pMHC interaction. However, Altman et al first demonstrated the ability to identify 
HIV specific CD8+ T cells by adopting a strategy of tetramerizing biotinylated peptide-
MHC complexes with fluorescently labeled streptavidin molecules (6). Since then, 
pMHC-tetramers have been invaluable in T cell biology research and also in clinical 
research including epitope discovery and mapping, vaccine and therapeutic 
development, and the analysis of disease responses (54). Multimerization of pMHC 
complexes have also since evolved with numerous formats being developed based on 
increasing the valency of interaction. Dimer pMHC complexes, using IgG as a molecular 
scaffold, were developed not long after pMHC tetramers, and have been 
commercialized by BD Biosciences as DimerX (116). Other groups adopted various 
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different scaffolds with which valency was increased that of tetramers. These include 
the pentameric pMHC (ProImmune), dextran conjugated dextramers (Immudex) and 
streptavidin-coated quantum dot conjugates, with the latter two reagents having 
between 20-30 pMHCs per conjugate (38, 176, 203). In many of these studies, it is 
likely that CD8 on the surface of the T cells also contributed to the binding of the 
multimeric pMHC (53). For purposes of in vitro engineering, for example by yeast 
display, there are additional problems with the use of these multimeric pMHC forms. 
CD8 is not available in the display systems, it is possible that TCR surface densities are 
below that found on T cells, and yeast cells do not have the membrane fluidity that 
allows improved multimeric detection. Accordingly, here I show the generation and 
application of a new multimeric reagent, based on streptavidin-coated fluorescent 
beads, that presents pMHCs at densities that are orders of magnitude higher than the 
aforementioned reagents, theoretically calculated to be ~2x104 per bead based on 
manufacturer’s specifications. 
 Preceding the generation of libraries for affinity maturation, it is useful to verify 
that wild type receptors are properly folded on the surface of the yeast cell. In the 
absence of clonotypic antibodies such as those against conformational epitopes of the 
2C TCR (108), or antibodies against conformational epitopes of the specific Vα and Vβ 
chains of the TCR of interest, the expression of functional TCRs on the surface of the 
yeast cell requires the probing of the specific TCR:pMHC interaction. However, while 
wild type TCRs with low affinity can be detected on the surface of T cells using available 
multimeric pMHCs reagents, they fail to do so when such receptors are displayed on the 
surface of yeast cells (43, 94, 95), presumably due to the lack of contribution from co-
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receptor binding to pMHC, reduced densities, or minimal membrane fluidity. To address 
these issues, I demonstrated the ability to detect the low affinity TCR:pMHC interaction 
between yeast display wild-type 2C TCR and the SIY/Kb pMHC complex (KD=30µM) 
using fluorescent pMHC beads. Thus, pMHC beads can be used as a probe for the 
expression of properly refolded of TCRs expressed in the yeast display system, as long 
as their affinities are above a threshold value of approximately 30 µM. While many wild-
type TCRs are in this range, it is important to note that some TCRs have affinities with 
KD values of 100 µM or even higher (32). 
 Dimeric and tetrameric pMHCs had been used for the isolation of high affinity 
mutants in the yeast display system of T cell engineering (94, 95), identifying mutations 
in CDR3α that bind to their cognate pMHC ligands with nanomolar affinities. In addition, 
it has been shown that mutations in CDR1 and CDR2 of both α and β chains of the TCR 
are also capable of enhancing binding affinities (47). Hence all six CDRs can be 
considered as potential targets for mutagenesis during library design for the engineering 
of high affinity TCRs. However, it is highly impractical to consider all CDRs as targets in 
a single library due to technical and practical considerations such as transformation 
efficiencies (107-108 transformants/µg plasmid in yeast display (14, 165)) and the speed 
of cell sorting without significant compromise to efficiency especially when collecting 
rare events (0.5-1% of cells sorted) (10). Thus, libraries design principles involve 
covering as many of the permutations as technically possible. In libraries where a higher 
affinity “solution” is below the sensitivity of reagents used during the screening process, 
it would not be selected. However, improved sensitivity with the pMHC beads would 
allow the isolation of such intermediate affinity mutants. These mutants can often be 
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used as leads upon which new libraries can be made for further enhancement. In 
addition, rational design of libraries that incorporates mutations identified in similar leads 
from individual libraries could be done to generate improved affinity mutants that would 
had been impossible from a single library (217). This strategy may be most useful when 
attempting to isolate de novo binders from naïve libraries. 
 Lastly, it is worth noting that there are applications in which the highest affinity 
solutions are not the most ideal target. In the application of soluble TCRs as a targeting 
tool, high affinity receptors are likely necessary, as stronger binding facilitate the 
detection of target cells and increase the efficacy of therapeutic payloads. In addition, 
as specific pMHC ligands on the surface of target cells are found in low numbers the 
use of multimeric TCR complexes would be impractical due to the lack of avidity. 
However, another possible application for affinity engineered TCRs is TCR gene 
therapy, where a patients’ T cells are transduced to express enhanced TCRs and 
reintroduced into the body where the modified T cells would elicit improved responses 
against virally infected or tumor cells (178). However, recent studies had cautioned 
against the use of high affinity receptors in such gene therapies. Zhao et al. showed that 
in CD8+ T cells expressing high affinity receptors lost antigen specificity while receptors 
with intermediate affinities (0.5 - 4µM) were able to maintain their specificity (166, 228). 
It has also been shown in our lab that cells expressing the high affinity m33 TCR 
showed cross-reactivity (94). Thomas et al. also demonstrated that while T cells 
expressing higher affinity receptors exhibited faster responses, their sensitivity to 
recognize antigens at low density was also affected (196). The ‘productive hit rate’ 
model states that serial engagement of TCRs is required for the amplification of 
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intracellular signals for T cell activation (206). In line with this model, Kalergis et al. and 
Dushek et al. proposed an explanation for the above observation by suggesting that an 
optimal koff or dwell time exists for efficient T cell activation (62, 107), beyond which the 
efficiency of serial engagement would be reduced and thus impaired T cell activation. 
Since T cell receptors with intermediate affinities were shown to confer co-receptor 
independence, allowing CD8- and CD4+ cells to respond to antigen stimulation (43, 166, 
228), the use of TCRs with intermediate affinities may be more ideal in TCR gene 
therapy.  
 In summary, pMHC beads for sorting of TCR libraries provides a screening 
strategy would allow us to isolate a broader range of TCRs with higher affinity, useful as 
intermediate leads in further engineering for soluble TCRs applications, and also 
providing intermediate affinity TCRs for use in adoptive T cell therapies with transduced 
TCRs. 
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Figure 4.1. Production of pMHC conjugated beads. Inclusion bodies of Kb 
and HLA-A*02:01 heavy chains and β2m were refolded with excess of 
peptides and purified. (A) Biotinylation was done in vitro by enzymatic 
conjugation with biotin ligase. Level of biotinylation was then probed by a gel 
shift assay done using SDS-PAGE in the presence and absence of excess 
streptavidin. (B) Schematic of pMHC coated fluorescent beads. (C) Level of 
pMHC conjugation can be probed by staining with an anti-β2m antibody. 
Beads were loaded with a titration of pMHC concentrations, from 5:1 to 
0.0005:1 pMHC to biotin binding site ratio, generating beads with various 
density of pMHCs. 
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Figure 4.2. Detection of yeast displayed single chain T cell receptors with 
multimeric pMHC detection reagents. 2CT7 scTCR with wild-type affinity of 
30µM along with the higher affinity variants Y48A (3µM) and m33 (30nM) were 
stained with equal concentrations of SIY/Kb presented in three different forms 
of conjugations. Comparison shows that at the same concentration of pMHC 
used, the coated beads was the only one that was able to detectably bind all 
three TCRs displayed on yeast cells. 
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Figure 4.3. Staining of yeast displayed 2C TCR and higher affinity 
mutants with pMHC beads presenting SIY peptide variants. (A) Structure 
of the 2C-SIY/Kb complex (PDB code: 1G6R) highlighting the protrusion of the 
side chains of Arg at position 4 and Tyr at position 6 of the SIY peptide toward 
the TCR (α chain in cyan, β chain in blue). (B) Refolded recombinant Kb in 
presenting wild-type SIY, R4A and Y6A variants were conjugated onto 
streptavidin coated beads to saturation. 2CT7, Y48A and m33 were stained 
with equal concentrations of SIY Kb presenting wild type and single Ala 
substituted peptide variants Y6A (D) and R4A (E). 
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Figure 4.4. Sensitivity of pMHC beads. (A) Yeast cells expressing 2CT7, 
Y48A and m33 cells were stained with varying numbers of beads saturated 
with pMHC. Theoretical pMHC concentrations presented by the beads were 
calculated based on manufacturer’s specifications. (B) Density of pMHC 
presented by beads were varied by titrating the concentration of biotinylated 
pMHC used for conjugation, starting with 5 fold excess, and subsequently 
used to stain the yeast cells. 
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Figure 4.5. Sorting an A6 scTCR library with Tax/A2 beads. (A) The A6 
scaffold library was stained with beads saturated with Tax/A2 and C18/A2 
pMHCs. (B) 108 cells were sorted with the top 1% of binders were collected 
during the first two rounds and top 0.5% of binders collected in the 3rd and 4th 
rounds. After 4 sorts, yeast cells that were binding Tax/A2 beads were 
enriched but not for Core18/A2 beads. 
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Figure 4.6. Analysis of clones isolated from A6 scTCR library using Tax/
A2 pMHC beads. 20 clones were picked from individual colonies isolated from 
the cells collected enriched from the A6 scaffold library for binding to Tax/A2 
pMHC coated beads. Strong binders with binding profiles similar to the original 
A6 X15 clone were observed in at least 50% of the clones isolated while 20% 
of the clones were found to be able to bind pMHC coated beads moderately 
well but poorly to tetramers.  
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Figure 4.7. Beads and tetramer titration analysis of 3 strong and 3 
intermediate binding clones. Clones H4-1, H4-3 and H4-11 (A) and clones 
H4-9, H4-12 and H4-20 (B) were stained with a titration of Tax/A2 pMHC 
tetramers (left panel) and Tax/A2 pMHC coated beads (right panel). Clones 
H4-1, H4-3 and H4-11 showed similar binding affinity as the high affinity A6 
X15 clone (black). C18/A2 pMHC coated beads were used as controls (ctrl).  
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Figure 4.8. Sorting a full length C18/A2 TCR library sorting with C18/A2 
beads . (A) Full length wild type C18/A2 specific TCR was expressed on the 
surface of yeast cells with the β chain tethered to the AGA complex and the α 
chain secreted. Association of the 2 chains was facilitated by an engineered 
disulfide bond (red line). (B) Expression was probed by antibodies against c-
myc (α chain), Vβ and HA (β chain). Yeast cells sorted for c-myc expression 
and immediately stained with C18/A2 beads did not show improved staining. 
(B) Expression of α and β chains in 2 full length CDR3α libraries, Lα1 and Lα2. 
(C) Lα1 and Lα2 were subjected to 4 rounds of sorting, isolating the top 1% 
binders for the first 2 sorts and the top 0.5% binders in the 3rd and 4th sorts. No 
enrichment was observed for both libraries after 4 sorts. 
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Library Sequence 
Wild type  LSGSARQ!
Lα1 XXXXARQ!
Lα2 LSGXXXX!
Table 4.1. HBV Core 18-27 specific TCR CDR3α library design. Two libraries 
were made with 4 amino acids randomized (X) at positions covering the length 
CDR3α sequences. 
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